var title_f9_41_9872="Placement of second clip";
var content_f9_41_9872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Placement of a second Hulka clip for sterlization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    lacement of a second Hulka clip for sterlization if first clip does not completely occlude the tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9872=[""].join("\n");
var outline_f9_41_9872=null;
var title_f9_41_9873="Rosacea keratitis - neovascularization";
var content_f9_41_9873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Rosacea keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Heavy neovascularization and mild opacity are present on the lower half of the cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9873=[""].join("\n");
var outline_f9_41_9873=null;
var title_f9_41_9874="Neonatal HSV brain CT";
var content_f9_41_9874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Computed tomography scan of the brain of a four-week-old infant with central nervous system (CNS) herpes simplex virus (HSV) infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography scan of the brain of a four-week-old infant with advanced destructive lesions of the brain associated with neonatal HSV infection of CNS. Infant presented with a one-week history of fever, seizures, and poor feeding. Cerebrospinal fluid showed mononuclear pleocytosis and elevated protein, and HSV DNA was detected by molecular PCR assay.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gail Demmler-Harrison, MD, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9874=[""].join("\n");
var outline_f9_41_9874=null;
var title_f9_41_9875="Atopic dermatitis infant";
var content_f9_41_9875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis - infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diaper area is relatively spared in this infant with widespread atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9875=[""].join("\n");
var outline_f9_41_9875=null;
var title_f9_41_9876="Ertapenem: Patient drug information";
var content_f9_41_9876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ertapenem: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     see \"Ertapenem: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/3/20533?source=see_link\">",
"     see \"Ertapenem: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      INVanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ertapenem or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11365 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9876=[""].join("\n");
var outline_f9_41_9876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166534\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015551\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015550\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015555\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015556\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015558\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015553\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015554\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015559\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015560\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=related_link\">",
"      Ertapenem: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/3/20533?source=related_link\">",
"      Ertapenem: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_41_9877="Ado-trastuzumab emtansine: Patient drug information";
var content_f9_41_9877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ado-trastuzumab emtansine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"     see \"Ado-trastuzumab emtansine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16253283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kadcyla&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F16342525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16342536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16342526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4200577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ado-trastuzumab emtansine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may interact with other drugs or health problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16342527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4200580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 6 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16342528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16342529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4200584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain more than 5 pounds in 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling on legs or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16342530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be closely watched by your doctor while getting the shot.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16342531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16342532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16342533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88727 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9877=[""].join("\n");
var outline_f9_41_9877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16253283\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342525\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342536\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342526\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342527\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342528\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342529\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342530\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342531\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342532\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342533\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=related_link\">",
"      Ado-trastuzumab emtansine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_41_9878="Loa loa eye worm";
var content_f9_41_9878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Loa loa eye worm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagnosis of loiasis can be established by identifying a migrating adult worm in the subcutaneous tissue or conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: LWW's Organism Central, Koneman EW, Sutton DA, Fothergill AW (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9878=[""].join("\n");
var outline_f9_41_9878=null;
var title_f9_41_9879="Viral myositis";
var content_f9_41_9879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Viral myositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9879/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/41/9879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of muscle syndromes associated with viral infections ranges from benign commonly experienced myalgias to rhabdomyolysis with myoglobinuric renal failure.",
"   </p>",
"   <p>",
"    This topic will review the clinical, pathologic, and diagnostic features of these illnesses. The evaluation of adults and children with muscle weakness, as well as the causes, clinical manifestations, and diagnosis of rhabdomyolysis, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24425?source=see_link\">",
"     \"Etiology and evaluation of the child with muscle weakness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link\">",
"     \"Causes of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYALGIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate diffuse myalgias occur frequently during the prodrome or early phase of any acute viral infection. The back and proximal extremities are commonly involved, and mild muscle tenderness may occur without weakness or laboratory abnormalities suggestive of muscle inflammation or necrosis. These self-limited myalgias are probably due to the effect of viral-induced cytokines on muscle tissue, rather than to direct viral invasion of muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BENIGN ACUTE CHILDHOOD MYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intermediate muscle syndrome accompanying acute viral infections is primarily seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/2\">",
"     2",
"    </a>",
"    ]. It consists of marked pain and tenderness, usually localized to the calves. This presentation has been reported most commonly with influenza A or B infections. It is often seen during influenza epidemics and has been described with the 2009 to 2010 pandemic influenza A (H1N1) virus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/3\">",
"     3",
"    </a>",
"    ]. It occurs as the acute illness is subsiding, usually 24 to 48 hours after the resolution of the presenting symptoms of fever, cough, and coryza.",
"   </p>",
"   <p>",
"    Patients will often refuse to walk or will have difficulty walking due to pain or to true muscle weakness. The ankles are held in a plantar flexed position, and the patient will resist attempts to dorsiflex the ankle because of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Benign acute childhood myositis should be included in the differential diagnosis of children with sudden difficulty walking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle enzymes are elevated up to 20 to 30 times normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/7\">",
"     7",
"    </a>",
"    ]. However, myoglobinuria and acute renal failure do not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/2\">",
"     2",
"    </a>",
"    ]. Muscle biopsy during the symptomatic phase reveals evidence of muscle necrosis and muscle fiber regeneration, with mild infiltration of polymorphonuclear or mononuclear leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/8\">",
"     8",
"    </a>",
"    ]. Full clinical recovery is typically seen in 3 to 10 days, with resolution of the elevated muscle enzymes within three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VIRAL MYOSITIS WITH RHABDOMYOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the other end of the clinical spectrum is viral myositis accompanied by massive rhabdomyolysis and its serious consequences. In a retrospective series from a pediatric emergency room, 38 percent of rhabdomyolysis cases were caused by viral myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This complication has been reported with the following viruses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Influenza A and B [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/10-13\">",
"       10-13",
"      </a>",
"      ], including H1N1 virus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coxsackievirus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Epstein-Barr virus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Herpes simplex virus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Parainfluenza [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adenovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Echovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cytomegalovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Measles [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Varicella-Zoster [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Human immunodeficiency virus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dengue [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of muscle necrosis in acute viral myositis has not been established with certainty. The following possibilities have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct invasion of muscle tissue by the viral agent. However, the presence of virus in affected muscle has been difficult to demonstrate consistently.",
"     </li>",
"     <li>",
"      Myotoxic cytokines released in response to viral infection. As an example, a case of rhabdomyolysis secondary to Coxsackievirus myositis has been reported in which the patient's serum contained an elevated level of tumor necrosis factor, which was capable of inducing skeletal muscle breakdown in an animal model [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunologic processes induced by the viral infection, which could result in muscle damage [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients present with a history of a preceding upper respiratory tract infection followed by high fever, diffuse myalgias, and anorexia. Gastrointestinal symptoms may also be present. This prodrome of viral symptoms occurs 1 to 14 days before the onset of signs and symptoms of rhabdomyolysis.",
"   </p>",
"   <p>",
"    Medical attention is typically sought because of the development of severe diffuse muscle pain, tenderness, or swelling that interferes with function or because of the development of pigmenturia. Others present with a life-threatening cardiac arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/30\">",
"     30",
"    </a>",
"    ] or alteration in mental status as a consequence of a metabolic derangement induced by the rhabdomyolysis. Some patients have a history of physical exertion in addition to viral symptoms prior to the development of muscle signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of muscle involvement is more diffuse than in the intermediate syndrome, in which involvement is limited to the legs. Both upper and lower extremities, as well as trunk muscles, are involved. Some patients present with abdominal pain due to abdominal muscle involvement. Muscles are tender and may be boggy or edematous in children. In severe cases, a compartment syndrome may develop as a result of muscle edema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/31\">",
"     31",
"    </a>",
"    ]. Weakness parallels the severity of muscle involvement.",
"   </p>",
"   <p>",
"    The course of acute viral myositis complicated by massive rhabdomyolysis is highly variable and relates to the course of the complications of rhabdomyolysis, including renal failure, fluid and electrolyte abnormalities, and cardiac arrhythmias. Other complications that can occur include respiratory failure secondary to respiratory muscle necrosis and weakness, infection, and pulmonary embolus. In most cases, muscle strength and renal function recover fully, usually within one to two weeks of the onset of rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute viral myositis as the cause of rhabdomyolysis is first suspected on a clinical basis. The history of a preceding viral infection or the presence of other manifestations of acute viral infection such as aseptic meningitis, myocarditis, or an exanthem in the absence of another explanation for muscle necrosis may be all that is necessary or possible to establish, with reasonable certainty, the presence of acute viral myositis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extreme elevations of creatine kinase (CK) can be seen in acute viral myositis with levels ranging from less than 10,000 international",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/32\">",
"     32",
"    </a>",
"    ] to more than 500,000 international",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/15\">",
"     15",
"    </a>",
"    ]. Transaminase elevations may also occur, as well as varying degrees of renal dysfunction. The classic findings on urinalysis include a dark-colored urine that tests positive for blood by dipstick, without red cells seen on microscopic examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512183#H11512183\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Urinalysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myoglobin may be detected in the urine. It can be distinguished clinically from hemoglobinuria by the presence of clear plasma. Myoglobin is a monomer that is not protein bound and is rapidly cleared in the urine. In comparison, hemoglobin is a dimer or tetramer that is also protein bound. These factors limit the degree to which hemoglobin is filtered; sufficient hemoglobin to discolor the urine does not occur until there are high enough plasma levels to discolor the plasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle biopsy can be entirely normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/33\">",
"     33",
"    </a>",
"    ] or may demonstrate varying degrees of necrosis ranging from scattered necrotic muscle fibers to widespread diffuse necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Nonspecific muscle fiber degeneration and regeneration, diffuse muscle cell vacuolization, and edema may be seen. Even in the presence of extensive necrosis, there is usually scant or no inflammatory cell infiltration. Since there are no specific diagnostic findings, muscle biopsy is seldom performed in suspected viral myositis, except to exclude other causes of rhabdomyolysis, such as an inherited metabolic myopathy or polymyositis.",
"   </p>",
"   <p>",
"    The laboratory can provide confirmatory or supportive evidence of acute viral infection. Isolation of the virus during the acute phase of the illness is a rapid and specific method to confirm the diagnosis of acute viral infection. Virus has been successfully isolated from the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/34\">",
"     34",
"    </a>",
"    ], throat [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/18\">",
"     18",
"    </a>",
"    ], cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/32\">",
"     32",
"    </a>",
"    ], and stool [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/20\">",
"     20",
"    </a>",
"    ] in cases of viral-associated rhabdomyolysis. The likelihood of successfully isolating a viral pathogen is greatest early in the course of the infection; this might account for the finding of negative cultures by the time the patient presents with rhabdomyolysis.",
"   </p>",
"   <p>",
"    Isolation of virus depends upon proper handling of appropriate specimens and the availability of a laboratory with viral culture capability. Isolation of a particular virus from a site in which it is rarely found is strong evidence of an acute infection, while isolation from a site where it may be found in asymptomatic individuals, such as enteroviruses in stool, provides less specific support for the diagnosis, which must then be confirmed by serologic testing.",
"   </p>",
"   <p>",
"    Evidence of a recent viral infection by serologic testing requires a fourfold increase in viral antibody titer between paired acute and convalescent specimens. If the initial titer is negative, a fourfold increase implies a primary infection with the virus. The infection is probably a reactivation if antibodies are present in low titer initially and if there is a significant rise during convalescence.",
"   </p>",
"   <p>",
"    Positive viral culture from muscle has been reported on only two occasions. In neither case was the clinical setting typical of acute viral myositis and rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/12,35\">",
"     12,35",
"    </a>",
"    ]. Viral or viral-like particles have been described on electron microscopy, but it is uncertain if these findings truly demonstrate the presence of viral pathogens in affected muscle or are artifacts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In most of the reports of acute viral myositis, no viral particles have been seen on biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis secondary to acute viral myositis must be distinguished from other causes of non-traumatic rhabdomyolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link&amp;anchor=H31734801#H31734801\">",
"     \"Causes of rhabdomyolysis\", section on 'Nontraumatic exertional rhabdomyolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link&amp;anchor=H31734822#H31734822\">",
"     \"Causes of rhabdomyolysis\", section on 'Nonexertional and nontraumatic rhabdomyolysis'",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Environmental heat illness and extreme physical exertion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drug-induced myopathies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Electrolyte abnormalities, such as hyperosmolality and hypokalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inherited metabolic myopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thyroid myopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link\">",
"       \"Hypothyroid myopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyomyositis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bacterial sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inflammatory myopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inherited metabolic myopathies typically cause recurrent episodes of myoglobinuria following exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    palmitoyltransferase (CPT) deficiency most closely resembles acute viral myositis because it can cause rhabdomyolysis in the absence of exertion, often in the setting of an acute bacterial or viral infection. A case of rhabdomyolysis occurring in a patient with both CPT deficiency and documented influenza has been reported and illustrates the overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/45\">",
"     45",
"    </a>",
"    ]. Muscle biopsy with special stains for CPT is necessary if there is a strong clinical suspicion of CPT deficiency.",
"   </p>",
"   <p>",
"    The inflammatory myopathies, dermatomyositis and polymyositis, rarely cause rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/46\">",
"     46",
"    </a>",
"    ]. The persistence of weakness and elevated muscle enzymes for more than one to two weeks after the onset of rhabdomyolysis decreases the likelihood of acute viral myositis and should lead to consideration of a chronic inflammatory myopathy.",
"   </p>",
"   <p>",
"    Both hypothyroidism and hyperthyroidism are rare causes of rhabdomyolysis. In the reported cases, rhabdomyolysis was precipitated either by an upper respiratory tract infection in an individual with thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/47\">",
"     47",
"    </a>",
"    ] or by vigorous exercise in a hypothyroid individual [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Representative case report",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 21-year-old woman was in good health until one week before admission when she developed malaise, fever, and a nonproductive cough. She was treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    for a presumed bronchitis. Two days before admission, she developed severe myalgias and began to pass dark tea-colored urine.",
"   </p>",
"   <p>",
"    There was no history of similar episodes of myalgias and pigmenturia. The patient was a college student and denied recent trauma, unusual physical activity, drug use, or a family history of muscle disease.",
"   </p>",
"   <p>",
"    On admission, she was alert, afebrile, and normotensive. She was unable to walk because of leg pain and was unable to rise from the supine position without assistance because of severe abdominal pain. There was no rash, and the heart and lung examinations were normal. There was diffuse tenderness of the muscles of all four extremities and of the abdominal wall muscles. There was no muscle swelling.",
"   </p>",
"   <p>",
"    Laboratory tests included hematocrit 40.5 percent, white blood cell count",
"    <span class=\"nowrap\">",
"     4700/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    erythrocyte sedimentation rate 12",
"    <span class=\"nowrap\">",
"     mm/hr,",
"    </span>",
"    sodium 140",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    potassium 4.2",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    creatinine 0.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (79",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    CK 640,000 international",
"    <span class=\"nowrap\">",
"     units/L,",
"    </span>",
"    aspartate aminotransferase (AST) 2715 international",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    and lactic dehydrogenase (LDH) 43,165 international",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"    The urine was dark brown and hematest positive. The sediment contained zero to two red blood cells per high power field and no casts. Chest x-ray, electrocardiogram, and electromyogram were normal. Blood cultures, viral throat cultures, toxic drug screen, and acute viral serologies for influenza A and B were all negative. Muscle biopsy was not performed.",
"   </p>",
"   <p>",
"    The patient was treated with aggressive intravenous hydration. The myalgias gradually resolved during the 10-day hospitalization. Urine output and renal function remained normal. Muscle enzymes rapidly decreased to CK 2915 international",
"    <span class=\"nowrap\">",
"     units/L,",
"    </span>",
"    AST 75 international",
"    <span class=\"nowrap\">",
"     units/L,",
"    </span>",
"    and LDH 606 international",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    at discharge. Four weeks after discharge, the patient felt entirely well with no muscle tenderness or weakness. CK had returned to normal. Convalescent influenza A titer showed a fourfold rise from the first sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHRONIC VIRAL MYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections caused by Echovirus and Human Immunodeficiency Virus (HIV) have been linked to chronic myositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echovirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echovirus has been associated with a chronic myopathy in patients with hypogammaglobulinemia that clinically can resemble idiopathic polymyositis or dermatomyositis. Most of the reported cases have occurred in males with x-linked recessive agammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/49\">",
"     49",
"    </a>",
"    ]. The muscle disease is usually preceded by viral meningoencephalitis.",
"   </p>",
"   <p>",
"    Echovirus has been cultured from the cerebrospinal fluid, muscle, blood, and urine of these patients. Serum CK levels may be normal or elevated. Muscle biopsy shows an inflammatory myopathy. Treatment with intravenous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrathecal gamma globulin may lead to a favorable clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9879/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory myopathy can occur in patients infected with the HIV virus. Like patients with idiopathic muscle inflammation, HIV infected patients may have progressive proximal muscle weakness involving the shoulder and hip girdles. They may also complain of nonspecific myalgias and abnormal laboratory findings including elevated muscle enzymes (eg, creatine kinase, aldolase, and aspartate transaminase) and abnormal electromyography. Muscle disease associated with HIV infection is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link\">",
"     \"Muscle disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95774402\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical spectrum of muscle syndromes associated with viral infections ranges from the commonly experienced benign myalgias to rhabdomyolysis with myoglobinuric renal failure. Mild to moderate self-limited diffuse myalgias, commonly involving the back and proximal extremities, occur frequently during the prodrome or early phase of any acute viral infection. Mild muscle tenderness, probably due to the effect of viral-induced cytokines, may occur without weakness or laboratory abnormalities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Myalgias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An intermediate and typically self-limited muscle syndrome accompanying acute viral infections is primarily seen in children; it consists of marked pain and tenderness, usually localized to the calves. This presentation has been reported most commonly with influenza A or B infections. Patients will often refuse to walk or will have difficulty walking due to pain or to true muscle weakness. Muscle enzymes are markedly elevated, and biopsies can show necrosis, regeneration, and mild cellular infiltration. However, myoglobinuria and acute renal failure do not occur. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Benign acute childhood myositis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral myositis accompanied by massive rhabdomyolysis and its serious consequences has been reported with more than a dozen different viruses. The mechanism of muscle necrosis in acute viral myositis is uncertain. Patients often present with an upper respiratory or gastrointestinal viral prodrome from one day to two weeks before the development of severe diffuse muscle pain, often involving the upper and lower extremities and the trunk, with tenderness or swelling that interferes with function; the presentation may include pigmenturia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Viral myositis with rhabdomyolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute viral myositis as the cause of rhabdomyolysis is first suspected on a clinical basis. Extreme elevations of CK can be seen, and transaminase elevations may also occur, as well as varying degrees of renal dysfunction and the presence of myoglobinuria, characterized by a dark-colored urine that tests positive for blood by dipstick, without red cells seen on microscopic examination. Myoglobin may be detected in the urine, and the laboratory can provide confirmatory or supportive evidence of acute viral infection. Rhabdomyolysis secondary to acute viral myositis must be distinguished from other causes of nontraumatic rhabdomyolysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections caused by echovirus and by human immunodeficiency virus have been linked to chronic myositis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Echovirus infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Human immunodeficiency virus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/1\">",
"      Stang H. Acute transient myositis associated with influenza virus infection. Pediatr Infect Dis J 1989; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/2\">",
"      Mackay MT, Kornberg AJ, Shield LK, Dennett X. Benign acute childhood myositis: laboratory and clinical features. Neurology 1999; 53:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/3\">",
"      Koliou M, Hadjiloizou S, Ourani S, et al. A case of benign acute childhood myositis associated with influenza A (H1N1) virus infection. Clin Microbiol Infect 2010; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/4\">",
"      Middleton PJ, Alexander RM, Szymanski MT. Severe myositis during recovery from influenza. Lancet 1970; 2:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/5\">",
"      Farrell MK, Partin JC, Bove KE. Epidemic influenza myopathy in Cincinnati in 1977. J Pediatr 1980; 96:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/6\">",
"      Zafeiriou DI, Katzos G, Gombakis N, et al. Clinical features, laboratory findings and differential diagnosis of benign acute childhood myositis. Acta Paediatr 2000; 89:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/7\">",
"      Dietzman DE, Schaller JG, Ray CG, Reed ME. Acute myositis associated with influenza B infection. Pediatrics 1976; 57:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/8\">",
"      Ruff RL, Secrist D. Viral studies in benign acute childhood myositis. Arch Neurol 1982; 39:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/9\">",
"      Mannix R, Tan ML, Wright R, Baskin M. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics 2006; 118:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/10\">",
"      Shenouda A, Hatch FE. Influenza A viral infection associated with acute renal failure. Am J Med 1976; 61:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/11\">",
"      Cunningham E, Kohli R, Venuto RC. Influenza-associated myoglobinuric renal failure. JAMA 1979; 242:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/12\">",
"      Gamboa ET, Eastwood AB, Hays AP, et al. Isolation of influenza virus from muscle in myoglobinuric polymyositis. Neurology 1979; 29:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/13\">",
"      Abe M, Higuchi T, Okada K, et al. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol 2006; 66:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/14\">",
"      D'Silva D, Hewagama S, Doherty R, et al. Melting muscles: novel H1N1 influenza A associated rhabdomyolysis. Pediatr Infect Dis J 2009; 28:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/15\">",
"      Fodili F, van Bommel EF. Severe rhabdomyolysis and acute renal failure following recent Coxsackie B virus infection. Neth J Med 2003; 61:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/16\">",
"      Friedman BI, Libby R. Epstein-Barr virus infection associated with rhabdomyolysis and acute renal failure. Clin Pediatr (Phila) 1986; 25:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/17\">",
"      McCabe JL, Duckett S, Kaplan P. Epstein-Barr virus infection complicated by acute rhabdomyolysis. Am J Emerg Med 1988; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/18\">",
"      Schlesinger JJ, Gandara D, Bensch KG. Myoglobinuria associated with herpes-group viral infections. Arch Intern Med 1978; 138:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/19\">",
"      O'Connor JV, Iyer SK. Myoglobinuria associated with parainfluenza type 2 infection. N Y State J Med 1982; 82:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/20\">",
"      Wright J, Couchonnal G, Hodges GR. Adenovirus type 21 infection. Occurrence with pneumonia, rhabdomyolysis, and myoglobinuria in an adult. JAMA 1979; 241:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/21\">",
"      Meshkinpour H, Vaziri ND. Association of myoglobinuria with adenovirus infection. West J Med 1982; 137:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/22\">",
"      Josselson J, Pula T, Sadler JH. Acute rhabdomyolysis associated with an echovirus 9 infection. Arch Intern Med 1980; 140:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/23\">",
"      Hughes GS Jr, Hunt R. Cytomegalovirus infection with rhabdomyolysis and myoglobinuria. Ann Intern Med 1984; 101:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/24\">",
"      Seibold S, Merkel F, Weber M, Marx M. Rhabdomyolysis and acute renal failure in an adult with measles virus infection. Nephrol Dial Transplant 1998; 13:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/25\">",
"      Hollenstein U, Thalhammer F, Burgmann H. Disseminated intravascular coagulation (DIC) and rhabdomyolysis in fulminant varicella infection--case report and review of the literature. Infection 1998; 26:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/26\">",
"      Mah&eacute; A, Bruet A, Chabin E, Fendler JP. Acute rhabdomyolysis coincident with primary HIV-1 infection. Lancet 1989; 2:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/27\">",
"      Guillaume MP, Van Beers D, Delforge ML, et al. Primary human immunodeficiency virus infection presenting as myopericarditis and rhabdomyolysis. Clin Infect Dis 1995; 21:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/28\">",
"      Acharya S, Shukla S, Mahajan SN, Diwan SK. Acute dengue myositis with rhabdomyolysis and acute renal failure. Ann Indian Acad Neurol 2010; 13:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/29\">",
"      Craighead JE, Huber SA, Sriram S. Animal models of picornavirus-induced autoimmune disease: their possible relevance to human disease. Lab Invest 1990; 63:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/30\">",
"      Hocking WG, Reza MJ. Letter: Nontraumatic rhabdomyolysis and renal failure. N Engl J Med 1975; 292:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/31\">",
"      Paletta CE, Lynch R, Knutsen AP. Rhabdomyolysis and lower extremity compartment syndrome due to influenza B virus. Ann Plast Surg 1993; 30:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/32\">",
"      Dunnet J, Paton JY, Robertson CE. Acute renal failure and Coxsackie viral infection. Clin Nephrol 1981; 16:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/33\">",
"      Tanaka T, Takada T, Takagi D, et al. Acute renal failure due to rhabdomyolysis associated with echovirus 9 infection: a case report and review of literature. Jpn J Med 1989; 28:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/34\">",
"      Christenson JC, San Joaquin VH. Influenza-associated rhabdomyolysis in a child. Pediatr Infect Dis J 1990; 9:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/35\">",
"      Kessler HA, Trenholme GM, Harris AA, Levin S. Acute myopathy associated with influenza A/Texas/1/77 infection. Isolation of virus from a muscle biopsy specimen. JAMA 1980; 243:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/36\">",
"      Greco TP, Askenase PW, Kashgarian M. Postviral myositis: myxovirus-like structures in affected muscle. Ann Intern Med 1977; 86:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/37\">",
"      Fukuyama Y, Ando T, Yokota J. Acute fulminant myoglobinuric polymyositis with picornavirus-like crystals. J Neurol Neurosurg Psychiatry 1977; 40:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/38\">",
"      Knochel JP. Environmental heat illness. An eclectic review. Arch Intern Med 1974; 133:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/39\">",
"      Schwaber MJ, Liss HP, Steiner I, Brezis M. Hazard of sauna use after strenuous exercise. Ann Intern Med 1994; 120:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/40\">",
"      Singhal PC, Abramovici M, Venkatesan J. Rhabdomyolysis in the hyperosmolal state. Am J Med 1990; 88:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/41\">",
"      Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/42\">",
"      Armstrong JH. Tropical pyomyositis and myoglobinuria. Arch Intern Med 1978; 138:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/43\">",
"      Naschitz JE, Yeshurun D, Shagrawi I. Rhabdomyolysis in pneumococcal sepsis. Am J Med 1989; 87:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/44\">",
"      Tein I, DiMauro S, DeVivo DC. Recurrent childhood myoglobinuria. Adv Pediatr 1990; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/45\">",
"      Kelly KJ, Garland JS, Tang TT, et al. Fatal rhabdomyolysis following influenza infection in a girl with familial carnitine palmityl transferase deficiency. Pediatrics 1989; 84:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/46\">",
"      Caccamo DV, Keene CY, Durham J, Peven D. Fulminant rhabdomyolysis in a patient with dermatomyositis. Neurology 1993; 43:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/47\">",
"      Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med 1984; 77:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/48\">",
"      Riggs JE. Acute exertional rhabdomyolysis in hypothyroidism: the result of a reversible defect in glycogenolysis? Mil Med 1990; 155:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9879/abstract/49\">",
"      Crennan JM, Van Scoy RE, McKenna CH, Smith TF. Echovirus polymyositis in patients with hypogammaglobulinemia. Failure of high-dose intravenous gammaglobulin therapy and review of the literature. Am J Med 1986; 81:35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5165 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FDEBE4EB0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9879=[""].join("\n");
var outline_f9_41_9879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95774402\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYALGIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BENIGN ACUTE CHILDHOOD MYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VIRAL MYOSITIS WITH RHABDOMYOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Representative case report",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHRONIC VIRAL MYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echovirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95774402\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24425?source=related_link\">",
"      Etiology and evaluation of the child with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_41_9880="Evaluation of the treatment-experienced patient with drug-resistant HIV infection";
var content_f9_41_9880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the treatment-experienced patient with drug-resistant HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9880/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9880/contributors\">",
"     Eric S Daar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9880/contributors\">",
"     Meena Lagnese, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9880/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9880/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/41/9880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11612312\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care in HIV management is to suppress plasma HIV RNA below the limits of assay detection in order to prevent the emergence of drug-resistant virus and disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This therapeutic goal becomes more difficult in the treatment-experienced HIV-infected patient with multidrug-resistant virus.",
"   </p>",
"   <p>",
"    However, advances in diagnostic testing and drug development have enabled great progress in the treatment of multidrug",
"    <strong>",
"     -",
"    </strong>",
"    resistant HIV infection. Drug discovery has focused on the development of new agents within existing drug classes and agents within novel drug classes with alternate mechanisms of antiviral action. Enhanced laboratory technologies have facilitated the evaluation of drug resistance mutations as well as viral tropism.",
"   </p>",
"   <p>",
"    The evaluation of the patient with a history of drug-resistant HIV infection will be reviewed here, while specific drug selection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug resistance testing, viral tropism, and specific mutations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of the treatment-naive patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612319\">",
"    <span class=\"h1\">",
"     DRUGS BY CLASS AND ABBREVIATIONS USED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following list includes the currently available antiretroviral agents by class and the common names and abbreviations that are used (",
"    <a class=\"graphic graphic_table graphicRef55550 \" href=\"UTD.htm?31/8/31883\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612326\">",
"    <span class=\"h2\">",
"     Nucleoside reverse transcriptase inhibitors (NRTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NRTI class includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      : ZDV; also known as AZT",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       Didanosine",
"      </a>",
"      : ddI",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"      : d4T",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      : 3TC",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      : ABC",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      : TDF",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       Emtricitabine",
"      </a>",
"      : FTC",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612333\">",
"    <span class=\"h2\">",
"     Nonnucleoside reverse transcriptase inhibitors (NNRTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NNRTI class includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      : NVP",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      : EFV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"       Delavirdine",
"      </a>",
"      : DLV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       Etravirine",
"      </a>",
"      : ETR",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612340\">",
"    <span class=\"h2\">",
"     Protease inhibitors (PIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PIs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       Saquinavir",
"      </a>",
"      : SQV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       Indinavir",
"      </a>",
"      : IDV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      : RTV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       Nelfinavir",
"      </a>",
"      : NFV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      : FPV",
"     </li>",
"     <li>",
"      Lopinavir plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (fixed dose combination):",
"      <span class=\"nowrap\">",
"       LPV/r",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      : ATV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      : TPV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      : DRV",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612347\">",
"    <span class=\"h2\">",
"     Fusion inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only fusion inhibitor is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"       Enfuvirtide",
"      </a>",
"      : ENF, also known as T-20 (fusion inhibitor)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612354\">",
"    <span class=\"h2\">",
"     CCR5 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only CCR5 receptor antagonist available to date is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"       Maraviroc",
"      </a>",
"      : MVC",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612361\">",
"    <span class=\"h2\">",
"     Integrase strand transfer inhibitors (INSTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only integrase inhibitor available to date is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      : RAL",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612368\">",
"    <span class=\"h1\">",
"     DEFINITION OF THE TREATMENT-EXPERIENCED PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are considered treatment-experienced have received at least one antiretroviral regimen in the past. Whether the patient has developed resistance on the prior regimen will depend on: a) whether they achieved viral suppression or not and b) their level of adherence. Those with detectable viremia and low levels of adherence typically have a lower risk of developing resistance compared with patients with intermediate levels of adherence. Patients with viremia despite excellent adherence may have had drug resistance prior to treatment initiation, which was not detected by standard assays; drug resistance can be missed if the patient is tested off ART. (See",
"    <a class=\"local\" href=\"#H11612487\">",
"     'Use and interpretation of drug resistance testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The spectrum of drug resistance in an individual patient can range from minimal resistance that affects the activity of one or two drugs (eg, the M184V mutation associated with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ), to multidrug resistance to several drug classes (eg, NRTIs, NNRTIs and PIs). Patients who develop virologic failure while taking agents with a low genetic barrier to resistance, such as lamivudine, emtricitabine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    and all NNRTIs will more often than not have developed drug resistance to these agents.",
"   </p>",
"   <p>",
"    The management of this patient population will vary depending upon their history of tolerance to various drugs and the extent of resistance that they have accumulated, which may have an impact on the efficacy of other medications. Issues related to tolerance and adverse events are also addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11450821\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612382\">",
"    <span class=\"h2\">",
"     Historical perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several years ago, first and second-line therapy typically included thymidine analogues (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ) with first generation NNRTIs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ), or non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs. When insufficient viral suppression was achieved or viral rebound occurred, virus was often resistant to many, if not all, available drugs within these three classes. Subsequent regimens were often characterized by limited tolerability and poor adherence because of the number of drugs being administered, dosing frequency, and adverse effects of the medications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, virologic outcomes were poor since many of the drugs used within these treatment strategies only had partial activity.",
"   </p>",
"   <p>",
"    However, in the current treatment era, patients typically are starting better tolerated NRTIs with either NNRTIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs or integrase inhibitors with lower frequency of virologic failure and drug resistance. In fact, PI resistance is rare in these types of patients. In addition, virologic suppression in the patients with multidrug resistance can usually be achieved with ART regimens that have a lower pill burden and better overall tolerance. Treatment strategies that include medications from novel drug classes (eg, CCR5 inhibitors, INSTIs, fusion inhibitors), and later generation drugs within the older PI and NNRTI classes are highly efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11450837\">",
"    <span class=\"h2\">",
"     Incidence of treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increasing availability of potent antiretroviral medications, the incidence of multiple treatment failures continues to decline dramatically. In a large retrospective study, which included 13,165 patients who switched to a second regimen, 7156 developed virologic treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the crude incidence of experiencing treatment failure declined from 56 events in 1996 (95% CI, 50 to 63 events per 100 person-years) to 16 events in 2005 (95% CI, 14 to 18 events per 100 person-years). In addition, in the current treatment era, the risk of drug resistance among treatment-naive patients is much lower than in the past because of simpler dosing regimens that are highly effective and well tolerated; thus, the overall risk of drug resistance has declined among treatment-naive and treatment-experienced patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612396\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main goals of treatment in the HIV-infected patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of disease progression",
"     </li>",
"     <li>",
"      Attainment of complete virologic suppression to prevent further drug resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even in the patient with multidrug resistance, both goals are attainable in the current treatment era. Complete and sustained viral suppression are critically important, since patients who have persistent viremia while taking antiretroviral therapy inevitably develop increasing resistance to their medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13715036\">",
"    <span class=\"h1\">",
"     DEFINING VIROLOGIC FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients should have an HIV RNA level less than 200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (and ideally less than 50",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    within 24 weeks after starting or modifying a combination antiretroviral regimen.",
"   </p>",
"   <p>",
"    If viral suppression is not attained at this timepoint, the clinician should inquire about the patient&rsquo;s adherence. If the patient has been adherent with medications, the presence of HIV RNA &gt;200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    is consistent with virologic failure and the possibility of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, intermittent &ldquo;blips&rdquo; of low level of viremia (50 to 200",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    are generally not associated with the emergence of drug-resistant virus; thus, intermittent viral blips should not prompt a change in therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/9\">",
"     9",
"    </a>",
"    ]. Less is known regarding the relevance or management of persistent viremia in the range of 50 to 200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11451195\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing drug exposure in patients with persistent viremia can lead to accumulation of mutations and risk of cross-resistance to other agents within the same class. Prompt interventions with modification of ART help to decrease the risk of increasing drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11450857\">",
"    <span class=\"h1\">",
"     THERAPY OF TREATMENT-EXPERIENCED PATIENTS WITH DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the patient with multidrug-resistant virus requires expertise in complex HIV management and a thorough understanding of drug resistance testing assays in order to create an efficacious regimen. The initial approach requires a comprehensive evaluation of the patient's treatment history as well as past and current genotypic and phenotypic drug resistance testing. With this information, the clinician can determine which drugs are likely to be fully or partially active against the patient's viral strain. Resistance data can be further supplemented with a tropism test if a CCR5 antagonist is likely to be used in the next regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612403\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF DESIGNING AN EFFECTIVE REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to attain viral suppression, there are several principles that should guide drug selection and treatment strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612410\">",
"    <span class=\"h2\">",
"     Number of active agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral suppression is most likely to be achieved when three fully active drugs are utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective analyses have consistently shown a direct relationship between the number of active drugs included in a treatment regimen and the increased likelihood of achieving viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. If three fully active drugs are not available, at least two fully active drugs should be combined with other agents with partial activity.",
"   </p>",
"   <p>",
"    Immunologic benefit, as evidenced by elevations in CD4 cell counts, often occurs despite incomplete viral suppression. However, one study of 291 patients with virologic failure on a PI-containing regimen demonstrated that this immunologic benefit waned after three years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, it is always best attain complete viral suppression for the best long-term clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612417\">",
"    <span class=\"h2\">",
"     Avoid therapeutic pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of any single active drug in the setting of virologic failure will not result in durable viral suppression, but rather the emergence of further primary and accessory drug resistance mutations. This principle applies regardless of the potency of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612424\">",
"    <span class=\"h2\">",
"     Genetic barrier to resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs are more \"fragile\" than others due to a low genetic barrier to resistance; this implies that only a single mutation can lead to complete abrogation of drug potency (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/4,7,16\">",
"     4,7,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, other drugs require multiple mutations before efficacy is comprised (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs). In patients with extensive resistance, drugs with a high genetic barrier to resistance are favored, whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612438\">",
"    <span class=\"h1\">",
"     PATIENT READINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every effort must be made to be certain that the patient is ready, willing, and able to commit to treatment prior to initiation or modification of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/2\">",
"     2",
"    </a>",
"    ]. This issue is particularly important in the patient experiencing virologic failure where the initial lack of success may have resulted from poor adherence and where treatment options become limited. It is also critical to know why the prior regimen(s) failed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612445\">",
"    <span class=\"h1\">",
"     AVAILABLE ASSAYS TO ASSESS DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance testing determines which agents are likely to be active for a given patient; use of such testing is associated with improved virologic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. HIV drug resistance testing is discussed in detail elsewhere; a concise summary follows below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612452\">",
"    <span class=\"h2\">",
"     Genotypic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic resistance assays detect mutations in the coding regions for HIV reverse transcriptase, integrase, and protease that have been associated with drug resistance (eg, M184V mutation for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ). Genotypic testing is readily available and relatively inexpensive compared with phenotypic assays. However, interpretation becomes more complex with an increasing number of viral mutations.",
"   </p>",
"   <p>",
"    Standard genotypic assays do not give drug resistance testing results for INSTIs; a separate assay must be requested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612459\">",
"    <span class=\"h2\">",
"     Phenotypic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotypic testing detects the fold-change in drug susceptibility of the patient's virus relative to a wild-type control strain. The utility of these assays has improved as clinical cutoffs corresponding to fold-change susceptibility have been better defined for each available drug [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenotypic testing has a longer turnaround time and is more expensive than genotypic testing. However, phenotypic testing appears to give particularly beneficial information in the treatment-experienced patient with complex resistance patterns, particularly in the protease gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard phenotypic assays do not give drug resistance testing results for fusion inhibitors and INSTIs; a separate assay must be requested for each of these. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612466\">",
"    <span class=\"h2\">",
"     Virtual phenotype testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Virtual\" phenotypic testing uses genotypic data to determine the likely phenotype of a particular virus. This is accomplished by matching the patient isolate to viruses within a large database of previously studied samples that have paired genotypic and phenotypic information [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the value of virtual phenotype testing is limited with respect to newer drugs for which there are fewer matching genotypes and phenotypes in the database [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612473\">",
"    <span class=\"h2\">",
"     Tropism assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV requires both the CD4 receptor and a chemokine coreceptor in order to enter CD4 T-cells. This coreceptor can be CCR5 or CXCR4. Viruses that use CCR5 as their coreceptor are referred to as \"R5-tropic&rdquo; viruses; those that use CXCR4 are \"X4-tropic\" viruses. If an individual&rsquo;s blood contains a mixture of R5 and X4 viruses they are mixed-tropic and if a single virus can use either receptor it is referred to as dual-tropic. Most assays cannot distinguish between mixed and dual-tropic so they are referred to as",
"    <span class=\"nowrap\">",
"     dual/mixed.",
"    </span>",
"   </p>",
"   <p>",
"    Testing for viral tropism is strongly recommended when considering the use of a CCR5 antagonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , which only inhibits R5 virus. At this time CCR5 antagonists should NOT be recommended for those patients that have detectable CXCR4-using virus, ie, those who are reported as X4 or",
"    <span class=\"nowrap\">",
"     dual/mixed",
"    </span>",
"    tropic.",
"   </p>",
"   <p>",
"    Currently, most validated assays assess phenotypic tropism, but there is increasing data demonstrating the potential utility of genotypic tropism testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of HIV drug resistance testing assays\", section on 'Tropism assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612480\">",
"    <span class=\"h2\">",
"     Assessment of replication capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of replication capacity is reported on one commercially available drug resistance tropism test. At this time it is unclear how these data may be used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612487\">",
"    <span class=\"h1\">",
"     USE AND INTERPRETATION OF DRUG RESISTANCE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612496\">",
"    <span class=\"h2\">",
"     When to perform drug resistance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is currently recommended that testing be performed in treatment-na&iuml;ve individuals to identify the presence of transmitted resistant virus. In treatment-experienced patients, testing should be performed at a time when plasma HIV RNA is at least 500",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and while the patient is still taking antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Resistance testing is less accurate in the absence of drug pressure; thus, the presence of low levels of resistant virus cannot be excluded among those patients who are not on antiretroviral therapy at the time of testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612503\">",
"    <span class=\"h2\">",
"     Types of drug resistance mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mutations confer resistance to only select drugs. For example, the M184V mutation confers resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and the K103N mutation confers resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    . Other drug resistance mutations may confer broad cross-resistance within an entire class. As an example, the K65R mutation results in drug resistance to many NRTIs.",
"   </p>",
"   <p>",
"    Amongst the PIs, the impact of drug resistance mutations is more complex. Major mutations, which tend to emerge early during treatment with non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs, may lead to a substantial reduction in virus susceptibility to that particular PI. Minor mutations alone may not significantly impact drug susceptibility; however, minor mutations in combination with major resistance mutations can lead to increasing overall drug resistance and cross-resistance to other agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612510\">",
"    <span class=\"h2\">",
"     Medication history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance testing does not replace a thorough assessment of a patient's past drug treatment history since these assays may miss minority drug-resistant species within a viral population. A detailed medication history and drug resistance testing should be considered complementary information. Any prior resistance mutations are considered valid even if not detected with more recent tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612517\">",
"    <span class=\"h1\">",
"     CHOICE OF ASSAY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612526\">",
"    <span class=\"h2\">",
"     Choosing drug resistance assays in clinical practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents made the following recommendations for drug resistance testing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genotypic testing is the preferred drug resistance testing assay in patients with virologic failure while on their first or second regimens",
"     </li>",
"     <li>",
"      Both phenotypic and genotypic testing is preferred for persons with known or suspected complex drug resistance mutation patterns involving more than one class of drugs. This is particularly relevant for the patient with suspected multiple PI mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of which assay is used, HIV specialists should interpret the results of resistance testing using all available resources, including interpretative information from the clinical laboratory where the assay was performed and susceptibility databases such as those maintained by the International AIDS Society-USA Drug Resistance Mutations Group (",
"    <a class=\"external\" href=\"file://www.iasusa.org\">",
"     file://www.iasusa.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/24\">",
"     24",
"    </a>",
"    ] and Stanford University (",
"    <a class=\"external\" href=\"file://hivdb.stanford.edu\">",
"     file://hivdb.stanford.edu",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H822442\">",
"    <span class=\"h2\">",
"     Clinical history can define drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    , treatment history alone is usually adequate to predict HIV susceptibility since studies have demonstrated excellent activity in those who are treatment-naive compared with suboptimal activity in those who have experienced viral rebound or persistent viremia while taking enfuvirtide in the past. [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/25\">",
"     25",
"    </a>",
"    ]. Similarly, any patient that had been viremic in the past on medications with a low genetic barrier to resistance is likely to have underlying resistance to these drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H822455\">",
"    <span class=\"h1\">",
"     PREDICTORS OF VIROLOGIC SUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One retrospective study demonstrated that in addition to results of drug resistance testing, other factors that were associated with improved virologic response included [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9880/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low baseline viral load",
"     </li>",
"     <li>",
"      History of prior viral suppression",
"     </li>",
"     <li>",
"      Number of new medications administered",
"     </li>",
"     <li>",
"      Number of new drug classes used",
"     </li>",
"     <li>",
"      Tolerance and convenience of new regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this retrospective study, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs also correlated with better rates of viral suppression compared with NNRTIs (35 versus 12 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11612540\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of drug resistance in an individual patient can range from minimal resistance that affects the activity of one or two drugs (eg, the M184V mutation and resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ), to multidrug resistance to several drug classes (eg, NRTIs, NNRTIs and PIs). (See",
"      <a class=\"local\" href=\"#H11612368\">",
"       'Definition of the treatment-experienced patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the increased availability of potent antiretroviral medications, the incidence of multiple treatment failures continues to decline dramatically and viral suppression is feasible even among patients with multidrug resistance. (See",
"      <a class=\"local\" href=\"#H11450821\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main goals of treatment in the heavily treated HIV-infected patient include the prevention of disease progression and attainment of complete viral suppression to prevent further drug resistance. (See",
"      <a class=\"local\" href=\"#H11612396\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients should have an HIV RNA level &lt;200",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (and ideally less than 50",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      within 24 weeks after starting or modifying a combination antiretroviral regimen. If viral suppression is not attained at this timepoint, suboptimal medication adherence or viral resistance need to be considered. (See",
"      <a class=\"local\" href=\"#H13715036\">",
"       'Defining virologic failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial patient approach requires a thorough evaluation of the treatment history as well as past and current genotypic and phenotypic drug resistance testing. With this information, the clinician can determine which drugs are likely to be fully or partially active against the patient's viral strain. Resistance data can be further supplemented with a tropism test if a CCR5 antagonist is likely to be used in the next regimen. (See",
"      <a class=\"local\" href=\"#H11450857\">",
"       'Therapy of treatment-experienced patients with drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral suppression is most likely to be achieved when three fully active drugs are utilized. The addition of any single active drug in the setting of virologic failure is unlikely to result in durable viral suppression, but rather the emergence of further primary and accessory drug resistance mutations. This principle applies regardless of the potency of the drug.",
"     </li>",
"     <li>",
"      In treatment-experienced patients, resistance testing should be performed at a time when plasma HIV RNA is at least 500",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and while the patient is still taking antiretroviral therapy. Resistance testing is less accurate in the absence of drug pressure. (See",
"      <a class=\"local\" href=\"#H11612487\">",
"       'Use and interpretation of drug resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genotypic testing is the preferred drug resistance testing assay in patients with virologic failure while on their first or second regimens. Both phenotypic and genotypic testing is preferred for persons with known or suspected complex resistance mutation patterns involving more than one class of drugs. (See",
"      <a class=\"local\" href=\"#H11612517\">",
"       'Choice of assay'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/1\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, January 29, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/3\">",
"      Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/4\">",
"      Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/5\">",
"      Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/6\">",
"      Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/7\">",
"      Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/8\">",
"      Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009; 49:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/9\">",
"      Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817.",
"     </a>",
"    </li>",
"    <li>",
"     Ribaudo, H. Virologic failure endpoint definition in clinical trials. Presented at the 16th Conference on Retroviruses and Opportunistic Infections 2009 Abstract #580 (Accessed on January 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/11\">",
"      Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/12\">",
"      Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/13\">",
"      Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/14\">",
"      Fox ZV, Geretti AM, Kjaer J, et al. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS 2007; 21:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/15\">",
"      Mazzotta F, Lo Caputo S, Torti C, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003; 32:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/16\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/17\">",
"      Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/18\">",
"      Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/19\">",
"      Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/20\">",
"      Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/21\">",
"      Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005; 19:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/22\">",
"      Verbiest W, Peeters M, Hertogs K, et al. Virtual phenotype is concordant with actual phenotype: a retrospective analysis of data from VIRA 3001. Antivir Ther 2000; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on January 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/24\">",
"      Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/25\">",
"      Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9880/abstract/26\">",
"      Rhee SY, Fessel WJ, Liu TF, et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009; 200:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13975 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9880=[""].join("\n");
var outline_f9_41_9880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11612540\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612312\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612319\">",
"      DRUGS BY CLASS AND ABBREVIATIONS USED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612326\">",
"      Nucleoside reverse transcriptase inhibitors (NRTIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612333\">",
"      Nonnucleoside reverse transcriptase inhibitors (NNRTIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612340\">",
"      Protease inhibitors (PIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612347\">",
"      Fusion inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612354\">",
"      CCR5 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612361\">",
"      Integrase strand transfer inhibitors (INSTIs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612368\">",
"      DEFINITION OF THE TREATMENT-EXPERIENCED PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11450821\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612382\">",
"      Historical perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11450837\">",
"      Incidence of treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612396\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13715036\">",
"      DEFINING VIROLOGIC FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11451195\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11450857\">",
"      THERAPY OF TREATMENT-EXPERIENCED PATIENTS WITH DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612403\">",
"      PRINCIPLES OF DESIGNING AN EFFECTIVE REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612410\">",
"      Number of active agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612417\">",
"      Avoid therapeutic pitfalls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612424\">",
"      Genetic barrier to resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612438\">",
"      PATIENT READINESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612445\">",
"      AVAILABLE ASSAYS TO ASSESS DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612452\">",
"      Genotypic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612459\">",
"      Phenotypic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612466\">",
"      Virtual phenotype testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612473\">",
"      Tropism assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612480\">",
"      Assessment of replication capacity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612487\">",
"      USE AND INTERPRETATION OF DRUG RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612496\">",
"      When to perform drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612503\">",
"      Types of drug resistance mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612510\">",
"      Medication history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612517\">",
"      CHOICE OF ASSAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11612526\">",
"      Choosing drug resistance assays in clinical practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H822442\">",
"      Clinical history can define drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H822455\">",
"      PREDICTORS OF VIROLOGIC SUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11612540\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13975|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/8/31883\" title=\"table 1\">",
"      Approved ARV agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=related_link\">",
"      Clinical trials of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27994?source=related_link\">",
"      Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_41_9881="Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history";
var content_f9_41_9881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9881/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9881/contributors\">",
"     Scott D Ramsey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9881/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/41/9881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/41/9881/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/41/9881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer results from both genetic and environmental factors and their interaction. Genetic predisposition is the dominant risk factor for some individuals; however, environmental factors (including diet, exercise, smoking, and obesity) are stronger risk factors in most people [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A family history of colorectal cancer is common among the general population. In the United States, about 5 percent of adults (aged 20 to 79 years) report having a first or second-degree relative with colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/3\">",
"     3",
"    </a>",
"    ]; other countries have reported rates that are somewhat higher, with one study from the Netherlands reporting that 11.7 percent of adults aged 30 to 70 years had at least one first-degree relative with colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/4\">",
"     4",
"    </a>",
"    ]. This rate increases with age, reflecting the increasing chance that relatives will develop colorectal cancer as they get older.",
"   </p>",
"   <p>",
"    One in four patients with colorectal cancer was at increased risk because of a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 3 to 4 percent of patients with newly-diagnosed colorectal cancer have a cancer susceptibility syndrome caused by one of two autosomal dominant, highly penetrant genetic mutations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary nonpolyposis colon cancer (HNPCC) accounts for about 2 to 6 percent of colorectal cancers and an increased risk of other cancers as well [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial adenomatous polyposis (FAP) accounts for less than 1 percent of colorectal cancers; cancers are preceded by hundreds of polyps throughout the colon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that the remainder of the heritable risk for colorectal cancers, usually called &ldquo;familial&rdquo; or &ldquo;nonsyndromic familial&rdquo; colorectal cancer, results from one or more genetic polymorphisms with a higher prevalence, but lower penetrance, than genes for HNPCC or FAP. The interaction of these polymorphisms with environmental carcinogens is hypothesized to lead to colorectal cancer.",
"   </p>",
"   <p>",
"    With the exception of familial cancer syndromes FAP and HNPCC, it has been difficult to identify genes that confer risk for familial colorectal cancer because multiple genes are involved and interact with the environment (",
"    <a class=\"graphic graphic_table graphicRef82037 \" href=\"UTD.htm?18/15/18685\">",
"     table 1",
"    </a>",
"    ). Families share behaviors and environmental exposures along with their genes, and twin studies suggest that genetic factors do not account for much of the excess risk in people with a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion summarizes how risk can be estimated according to specific information in the family history, what is known about the molecular basis for familial colorectal cancer, and approaches to cancer prevention in people with a family history of colorectal cancer. Screening and surveillance strategies for patients and family members of patients with known genetic syndromes (HNPCC, FAP, Peutz-Jeghers syndrome, and familial juvenile polyposis coli) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history is one of several factors that contribute to the risk of colorectal cancer. A decision tool, applicable only to non-Hispanic whites, has been developed by the National Cancer Institute and incorporates data on age, diet, exercise, medication use, and colonoscopy results as well as family history in first-degree relatives to estimate risk for CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/8\">",
"     8",
"    </a>",
"    ]. This prediction model, like others, is based upon assumptions about the validity of estimates for individual risk or protective factors and their interactions. The model is the best available predictor of risk, but its accuracy is not known precisely.",
"   </p>",
"   <p>",
"    Clinicians can screen for a family history of colorectal cancer by asking a simple set of three questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have any blood relatives had colorectal cancer or a precancerous polyp?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If so:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How many, and were these first-degree relatives (parent, sibling, or child) or second-degree relatives (grandparent, cousin, niece, or nephew)?",
"     </li>",
"     <li>",
"      At what age were the cancers or polyps diagnosed?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This information should be used to decide whether the diagnosis of HNPCC or FAP should be pursued by aggressive screening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic testing (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Possibility of HNPCC or FAP'",
"    </a>",
"    below) and whether the patient should begin screening for colorectal cancer at an earlier age than average risk individuals. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These questions should be asked early in adult life, by age 40, because patients with a positive family history should begin colorectal cancer screening at a younger age than the usual age of 50 years for average risk people. The same questions should be repeated as the patient ages because cancers may have arisen in family members, and the recommended frequency for screening varies with patient risk. A study from a US national population-based cancer registry found that 2.1 percent of participants at age 30 met criteria for high-risk screening based upon a family history of colorectal cancer, but that 7.1 percent met these high-risk criteria at age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, changes in family history with relevance to screening evolve over time. The authors of this study recommend that the family history be updated at least every 5 to 10 years.",
"   </p>",
"   <p>",
"    Family history is often not elicited or incorporated in patient care. In a survey of patients aged 35 to 55 years enrolled in a multispecialty group practice, 39 percent of patients reported that they had not been asked about family history, 46 percent of patients with a strong family history did not know they should be screened at an earlier age, and 55 percent with a strong family history had not received appropriate screening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/10\">",
"     10",
"    </a>",
"    ]. The cost-effectiveness of taking a family history of colorectal cancer to screen for family history has been estimated at $58,000 per year of life gained, similar to that of other widely accepted technologies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Introduction of a computer decision support tool (Genetic Risk Assessment on the Internet with Decision Support) improved the number and appropriateness of referrals to a Genetics Clinic for patients with increased risk for colorectal or breast cancer in a randomized trial involving 45 general practice teams in the UK [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Size of risk according to family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of increased risk related to a family history depends upon the number of family members affected, whether they are first-degree relatives, and the age of onset in the relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In general, the increase in lifetime risk ranges from about two- to sixfold according to these factors. The results of a systematic review providing estimates of these risks are shown in a figure (",
"    <a class=\"graphic graphic_figure graphicRef59834 \" href=\"UTD.htm?39/63/40957\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/14\">",
"     14",
"    </a>",
"    ]. One study compared findings at screening colonoscopy of subjects (aged 45 to 75) with a first-degree relative with colon cancer, with screening colonoscopy in average risk controls; the odds ratio for advanced neoplasia in first-degree relatives was 2.41 (95% CI 1.69-3.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/16\">",
"     16",
"    </a>",
"    ]. Another study compared colonoscopy in siblings of patients who had CRC to siblings of people without CRC who had normal colonoscopy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/17\">",
"     17",
"    </a>",
"    ]. The prevalence of advanced neoplasm was higher in siblings of CRC patients (7.5 percent versus 2.9 percent, OR 3.07; 95% CI 1.5-6.3) and prevalence was higher if the index case was female or had a distal CRC.",
"   </p>",
"   <p>",
"    The highest familial risk is in people with multiple first-degree relatives or relatives who have developed colorectal cancer at a relatively young age (eg, younger than 50 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/15\">",
"     15",
"    </a>",
"    ]. Risk for colorectal cancer is greater for relatives of patients with colon, as compared to rectal, cancer. Colorectal cancers occurring in distant relatives, or a single first-degree relative at an older age (eg, &gt;60 years), also are associated with an increased risk. However, the magnitude (relative risk 1.82, 95% CI 1.47-2.25 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/14\">",
"     14",
"    </a>",
"    ]) is not large enough to change clinical advice or screening practices from those recommended for the general population, and a detailed family history is not indicated if only distant or older relatives are affected.",
"   </p>",
"   <p>",
"    However, patients&rsquo; reports of family history may be inaccurate, and family history by itself is not a strong predictor of who will develop colorectal cancer, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population based study in Connecticut in which relatives were sampled for confirmation using registries, Medicare databases, medical records, and death records, the sensitivity of patient report was 27.3 percent and the positive predictive value 53.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cohort study of 431,153 people ages 35 to 80 in the Utah Population Database found that family history was not a strong predictor of who would get colorectal cancer in the next 20 years, when viewed as either a relative risk or an absolute risk [",
"      <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/19\">",
"       19",
"      </a>",
"      ]. For example, 93.3 percent of people in the cohort had a familial relative risk of &lt;1, and less than 0.4 percent of the cohort had a familial relative risk &gt;3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Family history of colonic polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is commonly believed that patients who have a family member with an adenomatous colonic polyp may also be at increased risk for adenoma or colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Some guidelines recommend early-onset screening (age 40 years) for people with a family history of polyps in relatives &lt;60 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the magnitude of risk may be overestimated because of increased efforts to look for cancer in families who already have a history of colorectal neoplasia. Also, family history for colonic polyps may be inaccurate. In one study, the positive predictive value for self-reported polyp was 80.9 percent, and the negative predictive value was 85.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of whether having a first-degree relative with colorectal polyps increases the risk of colorectal cancer noted that while multiple case control studies have identified an increased risk of adenomas when family members have an adenoma, only two studies were found that directly addressed whether a family history of adenoma increases risk for colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/23\">",
"     23",
"    </a>",
"    ]. Both studies reported an increased risk, comparable with the risk associated with a family history of colorectal cancer, one study reporting a relative risk of 4.36 (95% CI 1.60-10.21) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/25\">",
"     25",
"    </a>",
"    ] and the other reporting an odds ratio of 2.27 (CI 1.01-5.09) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the potential inaccuracy of the family history, we suggest that patients whose only familial risk factor for colorectal cancer is a relative with a history of adenomatous polyp that is not clearly documented as an advanced adenoma (&ge;1 cm, or high-grade dysplasia or villous elements) be screened as an average-risk patient. Individuals who have a first-degree relative with a documented history of advanced adenoma should be screened similarly to those with a family history of colorectal cancer. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age at which familial cancers occur",
"    </span>",
"    &nbsp;&mdash;&nbsp;In people with a family history, colorectal cancers occur earlier in life, not uncommonly in the 40s or even the 30s (",
"    <a class=\"graphic graphic_figure graphicRef57102 \" href=\"UTD.htm?3/24/3470\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/26\">",
"     26",
"    </a>",
"    ]. This is the rationale for beginning screening at an earlier age than for people at average risk. If a first-degree relative had colorectal cancer before age 60, the family member's risk at age 40 is about the same as an average risk person's at age 50. Relative risk is greatest in the 30s and 40s and by the time people with a family history of colorectal cancer reach the 60s, the increase in relative risk has become much smaller. However, the absolute risk attributable to family history increases with age. For example, the risk of a 70 year old developing colorectal cancer in the next 10 years is about 9 percent if that person has at least two first-degree relatives with colorectal cancer, compared with 3 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Possibility of HNPCC or FAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary nonpolyposis colon cancer (HNPCC, Lynch syndrome) is an autosomal dominant condition associated with a 52 percent risk of developing CRC in women and a 69 percent risk in men. Women with HNPCC also have an increased risk of genitourinary cancers, especially endometrial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/27\">",
"     27",
"    </a>",
"    ]. HNPCC-related cancers account for 2 to 6 percent of colorectal cancers, occur relatively early in life (commonly in the 30s and 40s and with median age of onset 61 years in mutation-positive relatives (",
"    <a class=\"graphic graphic_figure graphicRef58291 \" href=\"UTD.htm?28/26/29101\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/27\">",
"     27",
"    </a>",
"    ]), and are more likely to occur in the proximal colon.",
"   </p>",
"   <p>",
"    Polyps are no more frequent with HNPCC, although their tendency to develop into cancer is increased. HNPCC is recognized by a strong family history of colorectal and other cancers (multiple family members, across generations, developing colorectal cancer at a relative early age) and can be confirmed by genetic testing if tissue is available from an affected relative. HNPCC is associated predominantly with an increased risk for cancers of the colorectum and endometrium, but cancers may also occur in the stomach, ovary, pancreas, ureter and renal pelvis, biliary tract, small bowel, and brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial adenomatous polyposis (FAP) is also a familial cancer, is inherited as an autosomal dominant gene, and accounts for less than 1 percent of colorectal cancers. Hundreds to thousands of polyps occur throughout the colon beginning as early as adolescence (",
"    <a class=\"graphic graphic_picture graphicRef59413 \" href=\"UTD.htm?8/19/8504\">",
"     picture 1",
"    </a>",
"    ). Tumors develop beginning in the 20s, and nearly 100 percent of people develop colorectal cancer, usually before age 50 (",
"    <a class=\"graphic graphic_figure graphicRef58291 \" href=\"UTD.htm?28/26/29101\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENETICS OF FAMILIAL COLORECTAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial colorectal cancer is neither purely genetic nor purely environmental. Rather, it results from the interaction of genetic and environmental causes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic basis for some forms of familial colorectal cancer (particularly familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer) have been well defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By contrast, results vary among studies evaluating the genetic basis for familial risk in families who do not have these conditions. Many of these studies were small, patients' genotypes and environmental exposures differed from study to study, and publication bias was detected for most association studies genetic variants, possibly contributing to the variable results (",
"    <a class=\"graphic graphic_table graphicRef82037 \" href=\"UTD.htm?18/15/18685\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]. A family history of breast cancer, or BRCA1 or 2 genes, do not appear to be associated with an increased risk of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More targeted studies of 11 polymorphisms identified by genome wide association studies found that, although most of the 11 were associated with increased risk, taken together they account for only a small proportion of familial aggregation of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/31\">",
"     31",
"    </a>",
"    ]. In one study, 10 low-penetrance loci accounted for only 9 percent of the variance in family risk of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An attractive hypothesis is that increased risk is associated with polymorphisms that encode enzymes responsible for the metabolic activation of carcinogens such as the polycyclic aromatic hydrocarbons found in cigarette smoke and cooked red meat [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/33\">",
"     33",
"    </a>",
"    ]. As an example, genetically-determined rapid acetylation by N-acetyltransferase enzymes appears to modify the risk of colorectal cancer associated with red meat consumption. A nested case-control study from the Physicians' Health Study found that neither rapid acetylation nor red meat consumption alone was a risk factor for colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/34\">",
"     34",
"    </a>",
"    ]. However, in men over age 60, consumption of more than one serving of red meat per day was associated with an increased risk in rapid acetylators (relative risk 5.82, 95% CI 1.11-30.6) but not in slow acetylators (RR 1.56, CI 0.62-3.93). Similar results were seen in a nested case-control study of women from the Nurses' Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recently, genome wide association studies (GWAS) have found polymorphisms across several chromosomes that have been consistently associated with colorectal cancer, although the magnitude of increased risk for each individual polymorphism is small (eg, relative risk &lt;2) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    ). The number of identified susceptibility genes is growing as more powerful studies are devised to find them. For example, a meta-analysis of three GWAS with 3334 cases and 4628 controls found four new CRC risk loci, in addition to the ten already identified, and evidence that other variants of similar effect size might be discovered in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/36\">",
"     36",
"    </a>",
"    ]. It is generally believed that familial colorectal cancer results from the effects of many low-penetrance genes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although identified polymorphisms apparently confer only a small increase in risk for an individual, they may be associated with substantial increase in population risk. Also, the occurrence of multiple polymorphisms in an individual could theoretically confer a substantial increase in that individual's risk, but this has not been demonstrated in epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/38\">",
"     38",
"    </a>",
"    ]. Therefore, we do not recommend testing for polymorphisms in persons who do not meet clinical criteria for genetic testing to identify familial cancer syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTOR MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is plausible that increased risk results from an inherited abnormality in response to environmental exposures. Thus, it is prudent to make a special effort to modify behavioral risk factors in people already at increased risk because of family history. As examples, patients should be encouraged to quit smoking reduce alcohol use, and increase fruit and vegetable consumption and physical activity. Survey suggests that patient may be receptive to modifying their behavior in response to understanding their risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    There is some evidence that postmenopausal hormone therapy prevents the development of colorectal neoplasia. The risks for increased cardiovascular disease with long-term use of hormone therapy, however, outweighs the small benefits regarding colorectal cancer prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonsteroidal anti-inflammatory drugs (NSAIDs) can decrease risk for colorectal neoplasia. However, the risks of long-term use of these drugs are generally thought to outweigh the benefits, even for persons with a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rationale for recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized, controlled trials of screening in people with a family history of colorectal cancer. Screening recommendations for people with a family history of colorectal cancer are based upon extrapolation from evidence of effectiveness in average risk people, modified by knowledge of how the biology of disease differs if a family history is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following general considerations are relevant in developing guidelines for screening people at increased risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is at risk for earlier onset CRC (eg, first-degree relative with onset of CRC before age 50), screening should begin earlier.",
"     </li>",
"     <li>",
"      If the patient is at risk for more rapid progression of disease (eg, HNPCC or FAP), screening should be performed more frequently.",
"     </li>",
"     <li>",
"      If the patient is at substantially increased risk (eg, HNPCC or FAP), screening should be with the best available test, colonoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening is begun earlier in people with a family history of early onset colorectal cancer since their risk at age 40 generally is comparable to an average-risk person's risk at age 50, when screening is usually begun. This is the basis for the general recommendation that screening begin at age 40 if there is a history of early colorectal cancer in a first-degree relative. A more specific recommendation is to begin screening 10 years before the age the cancer was diagnosed in the affected relative, to take into account the additional increase in risk related to especially early onset in the family member.",
"   </p>",
"   <p>",
"    One study used a computer simulation model (MISCAN-Colon) to model optimal screening strategies for patients with various combinations of number of affected first-degree relatives and age at cancer onset in affected relative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/4\">",
"     4",
"    </a>",
"    ]. In this study, the optimal strategy was colonoscopy every five years starting from age 50 for individuals with one first-degree relative diagnosed after age 50 years; colonoscopy every four years starting at age 45 for individuals with one first-degree relative diagnosed before age 50 years; every three years starting at age 45 for individuals with two or more first-degree relatives diagnosed after age 50 years; and every three years starting at age 42 for individuals with two or more first-degree relatives of whom at least one was diagnosed before age 50 years. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patients with a family history of FAP or HNPCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRC screening and prevention, as well as genetic screening for these patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recommendations of expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific screening recommendations have been published by several expert groups. In contrast to earlier published guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], more recent guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/43\">",
"     43",
"    </a>",
"    ] recommend a less aggressive approach to screening individuals with a family history of polyps or CRC after age 60. 2008 guidelines from the US Preventive Services Task Force [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/44\">",
"     44",
"    </a>",
"    ] and from the US Multi-Society Task Force on Colorectal Cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/45\">",
"     45",
"    </a>",
"    ] do not specifically address screening in patients with family history of CRC, other than highest-risk groups with known genetic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     American College of Gastroenterology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Gastroenterology (ACG) issued guidelines in 2008 for screening patients at high risk for colorectal cancer because of a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/43\">",
"     43",
"    </a>",
"    ]. These guidelines are similar to those published by the American Cancer Society [",
"    <a class=\"abstract\" href=\"UTD.htm?9/41/9881/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screen with colonoscopy.",
"     </li>",
"     <li>",
"      If a single first-degree relative was diagnosed at age 60 years or older with CRC or an advanced adenoma (&ge;1 cm, or high-grade dysplasia, or villous elements), screening with colonoscopy is recommended every 10 years beginning at age 50, consistent with one option for average risk screening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If a single first-degree relative was diagnosed before 60 years with CRC or an advanced adenoma, or two or more first-degree relatives had colorectal cancer or advanced adenomas at any age, screening with colonoscopy is recommended at age 40 or 10 years before the youngest relative's diagnosis, to be repeated every five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ACG recommended a less aggressive approach than has been proposed in older guidelines because the prevalence of small tubular adenomas (&lt;1 cm) is extremely high and small adenomas with only low-grade dysplasia do not increase risk for CRC. Patients are often not certain if affected family member had advanced adenomas, small tubular adenomas, or hyperplastic polyps. The ACG recommends that such patients receive screening as for average risk patients, except when there is an explicit history or medical report providing evidence that the family member had an advanced adenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One in four patients with colorectal cancer has a family history of colorectal cancer. Three to four percent of patients with colorectal cancer have one of two genetic syndromes caused by autosomal dominant genes: hereditary nonpolyposis colon cancer (HNPCC) and familial adenomatous polyposis (FAP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should be asked before age 40 years about family history to identify increased risk: Have any blood relatives had colorectal cancer or an adenoma? If so, how many, and were these first-degree relatives (parent, sibling, or child) or second-degree relatives (grandparent, cousin, niece, or nephew)? Questions should be repeated periodically and interpreted keeping in mind family size (which, if small, can cause false-negative reports) and the possibility of uncertain paternity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial colorectal cancer results from the interaction of genetic and environmental causes. Several polymorphisms have been identified that are statistically associated with colorectal cancer, but with the exception of HNPCC and FAP, these associations are weak, inconsistent, and account for little of the observed familial risk. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetics of familial colorectal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized, controlled trials of screening in people with a family history of colorectal cancer. Screening recommendations for these patients are extrapolated from studies and recommendations for average-risk patients, modified by the known biology of familial colorectal cancer. We suggest screening patients at increased risk more aggressively and initiating screening earlier than for patients at average risk (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a family history of colorectal cancer, we follow screening guidelines of the American College of Gastroenterology. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'American College of Gastroenterology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Individuals at highest risk with familial syndromes (HNPCC, FAP) should be screened for CRC with colonoscopy at frequent specified intervals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"       \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"       \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients at increased risk (a first-degree relative with colon cancer or advanced adenoma diagnosed at age &lt;60 years, or two first-degree relatives diagnosed at any age) should be advised to have screening colonoscopy starting at age 40 years, or 10 years younger than the earliest diagnosis in their family, whichever comes first. Colonoscopy should be repeated every five years.",
"     </li>",
"     <li>",
"      Individuals with only slightly increased risk (first-degree relative with colorectal cancer or advanced adenoma diagnosed at age &ge;60 years) should be advised to be screened as average-risk persons beginning at age 50 years, using colonoscopy every 10 years for screening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients whose only familial risk factor for colorectal cancer is a relative with a history of adenomatous polyp that is not clearly documented as an advanced adenoma (&ge;1 cm, or high-grade dysplasia or villous elements) be screened as an average risk patient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Family history of colonic polyps'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/1\">",
"      Little J, Faivre J. Family history, metabolic gene polymorphism, diet and risk of colorectal cancer. Eur J Cancer Prev 1999; 8 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/2\">",
"      Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/3\">",
"      Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med 2006; 8:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/4\">",
"      Wilschut JA, Steyerberg EW, van Leerdam ME, et al. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer 2011; 117:4166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/5\">",
"      Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/6\">",
"      Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/7\">",
"      Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:78.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.gov/colorectalcancerrisk (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/9\">",
"      Ziogas A, Horick NK, Kinney AY, et al. Clinically relevant changes in family history of cancer over time. JAMA 2011; 306:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/10\">",
"      Fletcher RH, Lobb R, Bauer MR, et al. Screening patients with a family history of colorectal cancer. J Gen Intern Med 2007; 22:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/11\">",
"      Ramsey SD, Burke W, Pinsky L, et al. Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/12\">",
"      Emery J, Morris H, Goodchild R, et al. The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary care. Br J Cancer 2007; 97:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/13\">",
"      St John DJ, McDermott FT, Hopper JL, et al. Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 1993; 118:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/14\">",
"      Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/15\">",
"      Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006; 42:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/16\">",
"      Armelao F, Paternolli C, Franceschini G, et al. Colonoscopic findings in first-degree relatives of patients with colorectal cancer: a population-based screening program. Gastrointest Endosc 2011; 73:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/17\">",
"      Ng SC, Lau JY, Chan FK, et al. Increased risk of advanced neoplasms among asymptomatic siblings of patients with colorectal cancer. Gastroenterology 2013; 144:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/18\">",
"      Mai PL, Garceau AO, Graubard BI, et al. Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 2011; 103:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/19\">",
"      Taylor DP, Stoddard GJ, Burt RW, et al. How well does family history predict who will get colorectal cancer? Implications for cancer screening and counseling. Genet Med 2011; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/20\">",
"      Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/21\">",
"      Ahsan H, Neugut AI, Garbowski GC, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/22\">",
"      Cottet V, Pariente A, Nalet B, et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 2007; 133:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/23\">",
"      Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Ann Intern Med 2012; 156:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/24\">",
"      Madlensky L, Daftary D, Burnett T, et al. Accuracy of colorectal polyp self-reports: findings from the colon cancer family registry. Cancer Epidemiol Biomarkers Prev 2007; 16:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/25\">",
"      Nakama H, Zhang B, Fukazawa K, Abdul Fattah AS. Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer. Eur J Cancer 2000; 36:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/26\">",
"      Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/27\">",
"      Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/28\">",
"      Mucci LA, Wedren S, Tamimi RM, et al. The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. J Intern Med 2001; 249:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/29\">",
"      Ramsey SD, Holmes RS, McDermott CL, et al. A comparison of approaches for association studies of polymorphisms and colorectal cancer risk. Colorectal Dis 2012; 14:e573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/30\">",
"      Niell BL, Rennert G, Bonner JD, et al. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2004; 96:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/31\">",
"      von Holst S, Picelli S, Edler D, et al. Association studies on 11 published colorectal cancer risk loci. Br J Cancer 2010; 103:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/32\">",
"      Niittym&auml;ki I, Kaasinen E, Tuupanen S, et al. Low-penetrance susceptibility variants in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/33\">",
"      Coles B, Nowell SA, MacLeod SL, et al. The role of human glutathione S-transferases (hGSTs) in the detoxification of the food-derived carcinogen metabolite N-acetoxy-PhIP, and the effect of a polymorphism in hGSTA1 on colorectal cancer risk. Mutat Res 2001; 482:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/34\">",
"      Chen J, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998; 58:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/35\">",
"      Chan AT, Tranah GJ, Giovannucci EL, et al. Prospective study of N-acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer. Int J Cancer 2005; 115:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/36\">",
"      Houlston RS, Cheadle J, Dobbins SE, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010; 42:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/37\">",
"      Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/38\">",
"      Kiss I, S&aacute;ndor J, Pajkos G, et al. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res 2000; 20:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/39\">",
"      Ramsey S, Blough D, McDermott C, et al. Will knowledge of gene-based colorectal cancer disease risk influence quality of life and screening behavior?. Findings from a population-based study. Public Health Genomics 2010; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/40\">",
"      Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/41\">",
"      Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/42\">",
"      Simmang CL, Senatore P, Lowry A, et al. Practice parameters for detection of colorectal neoplasms. The Standards Committee, The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1999; 42:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/43\">",
"      Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/44\">",
"      U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/41/9881/abstract/45\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Cororectal Cancer Early Detection: American Cancer Society recommendations for colorectal cancer early detection. Available at; file://www.cancer.org/cancer/colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/colorectal-cancer-early-detection-acs-recommendations (Accessed on November 06, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7572 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9881=[""].join("\n");
var outline_f9_41_9881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Size of risk according to family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Family history of colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age at which familial cancers occur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Possibility of HNPCC or FAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENETICS OF FAMILIAL COLORECTAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTOR MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rationale for recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients with a family history of FAP or HNPCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recommendations of expert groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - American College of Gastroenterology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7572\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7572|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/63/40957\" title=\"figure 1\">",
"      Risk of colon cancer assoc w fam history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/24/3470\" title=\"figure 2\">",
"      Incidence colon ca family hx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/26/29101\" title=\"figure 3\">",
"      CRC in genetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7572|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/19/8504\" title=\"picture 1\">",
"      Familial polyposis Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7572|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/15/18685\" title=\"table 1\">",
"      Difficulty replicating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_41_9882="Amiodarone: Pediatric drug information";
var content_f9_41_9882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amiodarone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"    see \"Amiodarone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27189?source=see_link\">",
"    see \"Amiodarone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cordarone&reg;;",
"     </li>",
"     <li>",
"      Nexterone&reg;;",
"     </li>",
"     <li>",
"      Pacerone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amiodarone Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Apo-Amiodarone&reg;;",
"     </li>",
"     <li>",
"      Ava-Amiodarone;",
"     </li>",
"     <li>",
"      Cordarone&reg;;",
"     </li>",
"     <li>",
"      Dom-Amiodarone;",
"     </li>",
"     <li>",
"      Mylan-Amiodarone;",
"     </li>",
"     <li>",
"      PHL-Amiodarone;",
"     </li>",
"     <li>",
"      PMS-Amiodarone;",
"     </li>",
"     <li>",
"      PRO-Amiodarone;",
"     </li>",
"     <li>",
"      ratio-Amiodarone;",
"     </li>",
"     <li>",
"      Riva-Amiodarone;",
"     </li>",
"     <li>",
"      Sandoz-Amiodarone;",
"     </li>",
"     <li>",
"      Teva-Amiodarone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class III",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Supraventricular tachycardia: Limited data available: Loading dose: 10-20 mg/kg/day in 2 divided doses for 7-10 days; dosage should then be reduced to 5-10 mg/kg/day once daily and continued for 2-7 months; this protocol was used in 50 infants (&lt;9 months of age) and neonates (as young as 1 day of life);",
"     <b>",
"      Note:",
"     </b>",
"     Patients who received a higher loading dose (20 mg/kg/day) were more likely to have a prolongation of the corrected QT interval (Etheridge, 2001);  further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Use with caution when administering amiodarone with other drugs that prolong the QT interval (consider consulting expert): Tachyarrhythmia, including junctional ectopic tachycardia (JET), paroxysmal supraventricular tachycardia (PSVT): Dose not well-established; further studies are needed; the following dose is derived from studies that included neonates, infants, and children (Etheridge, 2001; Figa, 1994; Haas, 2008; Kovacikova, 2009; Raja, 1994; Soult, 1995):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 5 mg/kg given over 60 minutes;",
"     <b>",
"      Note:",
"     </b>",
"     Bolus infusion rates should generally not exceed 0.25 mg/kg/minute unless clinically indicated; most studies used bolus infusion time of 60 minutes to avoid hypotension; may repeat initial loading dose to a maximum total initial load: 10 mg/kg; do not exceed total daily bolus of 15 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion (if needed): Initial: 5 mcg/kg/minute; increase incrementally as clinically needed; usual required dose: 10 mcg/kg/minute; range: 5-15 mcg/kg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Taper infusion as soon as clinically possible and switch to oral therapy if necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"      see \"Amiodarone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Calculate dose using body surface area for infants &lt;1 year of age: Loading dose: 10-15 mg/kg/day or 600-800 mg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 1-2 divided doses/day for 4-14 days or until adequate control of arrhythmia or prominent adverse effects occur; dosage should then be reduced to 5 mg/kg/day or 200-400 mg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     /day given once daily for several weeks; if arrhythmia does not recur, reduce to lowest effective dosage possible; usual daily minimal dose: 2.5 mg/kg; maintenance doses may be given for 5 of 7 days/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A more aggressive dosing regimen was used in infants (n=50; mean age: 1 &plusmn; 1.5 months) &lt;9 months of age, treated for various types of SVT; 90% of patients at discharge and 100% of patients within 3 months of discharge were free of tachycardia; however, patients who received a higher loading dose (20 mg/kg/day in 2 divided doses) were more likely to have a prolongation of the corrected QT interval (Etheridge, 2001); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.O.:",
"     <b>",
"      Note:",
"     </b>",
"     Use with caution when administering amiodarone with other drugs that prolong the QT interval (consider consulting expert)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PALS dose for treatment of pulseless VT or VF (PALS, 2010): 5 mg/kg (maximum: 300 mg/dose) rapid I.V. bolus or I.O.; may repeat up to a maximum daily dose of 15 mg/kg (",
"     <b>",
"      Note:",
"     </b>",
"     Maximum recommended daily dose in adolescents: 2.2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PALS dose for treatment of perfusing tachycardias (PALS, 2010): Loading dose: 5 mg/kg (maximum: 300 mg/dose) I.V. given over 20-60 minutes or I.O.; may repeat up to maximum daily dose of 15 mg/kg (",
"     <b>",
"      Note:",
"     </b>",
"     Maximum recommended daily dose in adolescents: 2.2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Tachyarrhythmia, including junctional ectopic tachycardia (JET), paroxysmal supraventricular tachycardia (PSVT): Dose not well-established; further studies are needed; the following dose is derived from Celiker, 1998; Figa, 1994; Haas, 2008; Kovacikova, 2009; Perry, 1996; Raja, 1994; Soult, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 5 mg/kg (maximum: 300 mg/dose) I.V. given over 60 minutes;",
"     <b>",
"      Note:",
"     </b>",
"     Bolus infusion rates should generally not exceed 0.25 mg/kg/minute unless clinically indicated; most studies used bolus infusion time of 60 minutes to avoid hypotension; may repeat initial loading dose to a maximum total initial load: 10 mg/kg; do not exceed total daily bolus of 15 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion (if needed): Initial: 5 mcg/kg/minute; increase incrementally as clinically needed; usual required dose: 10 mcg/kg/minute; range: 5-15 mcg/kg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Taper infusion as soon as clinically possible and switch to oral therapy if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     A multicenter study (Perry, 1996; n=40; mean age: 5.4 years) used an I.V. loading dose of 5 mg/kg that was divided into five 1 mg/kg aliquots, with each aliquot given over 5-10 minutes. Additional 1-5 mg/kg doses could be administered 30 minutes later in a similar fashion if needed. The mean loading dose was 6.3 mg/kg. A maintenance dose (continuous infusion of 10-15 mg/kg/day) was administered to 21 of the 40 patients. Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Lower loading and maintenance doses are preferable in women and all patients with low body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ACLS dose for pulseless VT or VF (ACLS, 2010): I.V. push, I.O.: Initial: 300 mg; if pulseless VT or VF continues after subsequent defibrillation attempt or recurs, administer supplemental dose of 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Upon return of spontaneous circulation, follow with an infusion of 1 mg/minute for 6 hours, then 0.5 mg/minute (mean daily doses &gt;2.1 g/day have been associated with hypotension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ACLS doses for perfusing tachycardias: I.V.: See manufacturer's recommendations below for ventricular arrhythmias, for loading dose and continuous infusion; ACLS also recommends: Bolus doses for hemodynamically stable VT or wide QRS tachycardia of uncertain origin (regular rhythm): 150 mg given over 10 minutes; may repeat as needed to a maximum of 2.2 g/24 hours; for pre-excited atrial fibrillation: Consider 150 mg I.V. over 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventricular arrhythmias (manufacturer's recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Loading dose: 800-1600 mg/day divided in 1-2 doses/day for 1-3 weeks, then 600-800 mg/day in 1-2 doses/day for 1 month; maintenance: 400 mg/day; lower doses are recommended for supraventricular arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Loading dose: 1050 mg delivered over 24 hours as follows: 150 mg given over 10 minutes (at a rate of 15 mg/minute) followed by 360 mg given over 6 hours (at a rate of 1 mg/minute); follow with maintenance dose: 540 mg given over the next 18 hours (at a rate of 0.5 mg/minute); after the first 24 hours the maintenance dose is continued at 0.5 mg/minute; additional supplemental bolus doses of 150 mg infused over 10 minutes may be given for breakthrough VF or hemodynamically unstable VT; maintenance dose infusion may be increased to control arrhythmia; mean daily doses &gt;2.1 g/day have been associated with hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrial fibrillation: Pharmacologic cardioversion (ACC/AHA/ESC Practice Guidelines):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Inpatient: 1.2-1.8 g/day in divided doses until 10 g total, then 200-400 mg/day maintenance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Outpatient: 600-800 mg/day in divided doses until 10 g total, then 200-400 mg/day maintenance; although not supported by clinical evidence, a maintenance dose of 100 mg/day is commonly used especially for the elderly or patients with low body mass (Fuster, 2006; Zimetbaum, 2007).",
"     <b>",
"      Note",
"     </b>",
"     : Other regimens have been described and may be used clinically:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     400 mg 3 times/day for 5-7 days, then 400 mg/day for 1 month, then 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     10 mg/kg/day for 14 days, followed by 300 mg/day for 4 weeks, followed by maintenance dosage of 200 mg/day (Roy, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 5-7 mg/kg over 30-60 minutes, then 1.2-1.8 g/day continuous infusion until 10 g total. Maintenance: See oral dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrial fibrillation prophylaxis following open heart surgery:",
"     <b>",
"      Note:",
"     </b>",
"     A variety of regimens have been used in clinical trials, including oral and intravenous regimens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Starting in postop recovery, 400 mg twice daily for up to 7 days. Alternative regimen of amiodarone: 600 mg/day for 7 days prior to surgery, followed by 200 mg/day until hospital discharge; has also been shown to decrease the risk of postoperative atrial fibrillation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Starting at postop recovery, 1000 mg infused over 24 hours for 2 days has been shown to reduce the risk of postoperative atrial fibrillation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recurrent atrial fibrillation: No standard regimen defined; examples of regimens include: Oral: Initial: 10 mg/kg/day for 14 days; followed by 300 mg/day for 4 weeks, followed by maintenance dosage of 200 mg/day (Roy, 2000). Other regimens have been described and are used clinically (ie, 400 mg 3 times/day for 5-7 days, then 400 mg/day for 1 month, then 200 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transition from I.V. to oral therapy: Optimal initial daily dose depends on I.V. dose administered and oral bioavailability; use the following as a guide for an initial daily dose, assuming patient received 0.5 mg/minute for the listed duration of I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;1 week infusion: 800-1600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 week infusion: 600-800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;3 week infusion: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment",
"     </b>",
"     : No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Dosage adjustment is probably necessary in substantial hepatic impairment. No specific guidelines available. If hepatic enzymes exceed 3 times normal or double in a patient with an elevated baseline, consider decreasing the dose or discontinuing amiodarone.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nexterone&reg;: 150 mg (100 mL); 360 mg (200 mL) [contains cyclodextrin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (3 mL, 9 mL, 18 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cordarone&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacerone&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacerone&reg;: 200 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cordarone&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152841.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152841.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Pacerone&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer at same time in relation to meals; do not administer with grapefruit juice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Adjust administration rate to patient's clinical condition and urgency; give slowly to patients who have a pulse (ie, perfusing arrhythmia). With perfusing arrhythmias (eg, atrial fibrillation, stable ventricular tachycardia), do not exceed recommended I.V. concentrations or rates of infusion listed below (severe hepatic toxicity may occur). Slow the infusion rate if hypotension or bradycardia develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulseless VT or VF:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants, Children, and Adolescents: Administer via rapid I.V. bolus.",
"     <b>",
"      Note:",
"     </b>",
"     PALS guidelines do not specify dilution of bolus dose; clinicians may consider ACLS recommended adult dilutions of 10-15 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W; however, adult data in this setting suggest administration of undiluted drug may be preferred (Dager, 2006; Skrifvars, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: May be administered rapidly and undiluted.",
"     <b>",
"      Note:",
"     </b>",
"     <i>",
"      The Handbook of Emergency Cardiovascular Care",
"     </i>",
"     (AHA, 2005) recommends dilution in 20-30 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W; however, in this setting, administering",
"     <b>",
"      undiluted",
"     </b>",
"     is preferred (Dager, 2006; Skrifvars, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Perfusing arrhythmias:",
"     </b>",
"     Information based on adult data: Injection must be diluted before I.V. use. Administer via central venous catheter, if possible; increased phlebitis may occur with peripheral infusions &gt;3 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W, but concentrations &le;2.5 mg/mL may be less irritating; the use of a central venous catheter with concentrations &gt;2 mg/mL for infusions &gt;1 hour is recommended. Maximum concentration for infusion: 6 mg/mL. An in-line filter has been recommended during administration for continuous infusions to reduce the incidence of phlebitis. Use glass or polyolefin bottles for infusions &gt;2 hours; the use of polyvinyl chloride tubing is recommended in adults. Must be infused via volumetric infusion device; drop size of I.V. solution may be reduced and underdosage may occur if drop counter-infusion sets are used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants, Children, and Adolescents: Administer loading dose over 20-60 minutes; no data regarding concentration for infusion are available; take adult concentrations into consideration when diluting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Usual dilutions: First loading infusion: 150 mg in 100 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W (1.5 mg/mL) for infusion over 10 minutes; then 900 mg in 500 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W (1.8 mg/mL) to deliver rest of dose",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1.8 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F133689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference):",
"     </b>",
"     D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatible:",
"     </b>",
"     Amikacin, amphotericin B, atracurium, atropine, calcium chloride, calcium gluconate, caspofungin, ciprofloxacin, clindamycin, dexmedetomidine, diltiazem, dobutamine, dopamine, doripenem, doxycycline, epinephrine, eptifibatide, erythromycin lactobionate, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, gentamicin, hetastarch in lactate electrolyte injection (Hextend&reg;), insulin (regular), isoproterenol, labetalol, lepirudin, lidocaine, lorazepam, methylprednisolone sodium succinate, metoprolol, metronidazole, midazolam, milrinone, morphine, nesiritide, nitroglycerin, norepinephrine, pancuronium, penicillin G potassium, phentolamine, phenylephrine, potassium chloride, procainamide, tirofiban, tobramycin, vancomycin, vasopressin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, ampicillin and sulbactam, argatroban, bivalirudin, ceftazidime, digoxin, drotrecogin alfa, heparin, imipenem and cilastatin, micafungin, pantoprazole, piperacillin, piperacillin and tazobactam, potassium phosphate, sodium bicarbonate, sodium phosphate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefazolin, ceftriaxone, cefuroxime, furosemide, magnesium sulfate, nitroprusside.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Visually compatible (Chalmers, 2001):",
"     </b>",
"     Amphotericin B, atracurium, atropine, calcium chloride, calcium gluconate, ciprofloxacin, epinephrine, eptifibatide, famotidine, fentanyl citrate, fluconazole, furosemide (1 mg/mL), lepirudin, lorazepam, magnesium sulfate (20 mg/mL), methylprednisolone sodium succinate, milrinone, sodium nitroprusside, tirofiban, vasopressin, vecuronium.",
"     <b>",
"      Visually incompatible:",
"     </b>",
"     Ampicillin and sulbactam, ceftazidime, digoxin, furosemide (10 mg/mL), imipenem and cilastatin, magnesium sulfate (500 mg/mL), piperacillin, piperacillin and tazobactam, potassium phosphate, sodium phosphate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, heparin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Storage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; dispense in a light-resistant, tightly closed container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light during storage; protect from excessive heat; there is no need to protect diluted solutions from light during I.V. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Compatibility: Injection is compatible in D",
"     <sub>",
"      5",
"     </sub>",
"     W at concentrations of 1-6 mg/mL for 24 hours in glass or polyolefin bottles and for 2 hours in polyvinyl chloride bags; although amiodarone adsorbs to polyvinyl chloride tubing, all clinical studies used polyvinyl chloride tubing and the recommended doses take adsorption into account, therefore, in adults, polyvinyl chloride tubing is recommended",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Management of life-threatening recurrent ventricular arrhythmias [eg, recurrent ventricular fibrillation (VF) or recurrent hemodynamically unstable ventricular tachycardia (VT)] unresponsive to other therapy or in patients intolerant to other therapy (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Initiation of management and prophylaxis of frequently recurrent VF and hemodynamically unstable VT unresponsive to other therapy; VF and VT in patients requiring amiodarone who are not able to take oral therapy (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Also has been used to treat supraventricular arrhythmias unresponsive to other therapy. Amiodarone is recommended in the PALS guidelines for SVT (unresponsive to vagal maneuvers and adenosine). It is recommended in both the PALS and ACLS guidelines for cardiac arrest with pulseless VT or VF (unresponsive to defibrillation, CPR, and vasopressor administration) and control of hemodynamically-stable monomorphic VT or wide-complex tachycardia of uncertain origin. The drug is also recommended in the ACLS guidelines for re-entry SVT (unresponsive to vagal maneuvers and adenosine); control of rapid ventricular rate due to conduction via an accessory pathway in pre-excited atrial arrhythmias; control of stable narrow-complex tachycardia; and control of polymorphic VT with a normal QT interval.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amiodarone may be confused with aMILoride, inamrinone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cordarone&reg; may be confused with Cardura&reg;, Cordran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F133688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a recent meta-analysis, adult patients taking lower doses of amiodarone (152-330 mg daily for at least 12 months) were more likely to develop thyroid, neurologic, skin, ocular, and bradycardic abnormalities than those taking placebo (Vorperian, 1997). Pulmonary toxicity was similar in both the low-dose amiodarone group and in the placebo group but there was a trend towards increased toxicity in the amiodarone group. Gastrointestinal and hepatic events were seen to a similar extent in both the low-dose amiodarone group and placebo group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: AV block, bradycardia, cardiac arrhythmia, conduction abnormalities, CHF, edema, flushing, hypotension, SA node dysfunction; additional effects associated with I.V. administration include asystole, atrial fibrillation, cardiac arrest, electromechanical dissociation, pulseless electrical activity (PEA), ventricular tachycardia, and cardiogenic shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal gait/ataxia, dizziness, fatigue, headache, impaired memory, involuntary movement, insomnia, malaise, peripheral neuropathy, poor coordination, sleep disturbances, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, slate blue skin discoloration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperthyroidism, hypothyroidism, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal salivation, abnormal taste (oral), anorexia, constipation, diarrhea, nausea (I.V.), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Coagulation abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST or ALT level &gt;2x normal, hepatitis and cirrhosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis (I.V., with concentrations &gt;3 mg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Corneal microdeposits, halo vision, optic neuritis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Alveolar pneumonitis, ARDS, hypersensitivity pneumonitis, interstitial pneumonitis, pulmonary fibrosis (cough, fever, malaise), pulmonary inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal smell (oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute intracranial hypertension (I.V.), acute renal failure, acute respiratory distress syndrome, agranulocytosis, alopecia, anaphylactic shock, angioedema, aplastic anemia,  bone marrow granuloma, bronchiolitis obliterans organizing pneumonia (BOOP), bronchospasm, cholestatic hepatitis, confusion, delirium, demyelinating polyneuropathy, disorientation, drug rash with eosinophilia and systemic symptoms (DRESS),  dyspnea, encephalopathy, eczema, eosinophilic pneumonia, epididymitis (noninfectious), erectile dysfunction, erythema multiforme, exfoliative dermatitis, fever, granuloma, hallucination, hemolytic anemia, hemoptysis, hyperglycemia, hypertriglyceridemia, hypotension (oral), hypoxia, impotence, injection site reactions, leukocytoclastic vasculitis, muscle weakness, myopathy, neutropenia, optic neuropathy, pancreatitis, pancytopenia, parkinsonian symptoms, photophobia, pleural effusion, pleuritis, proarrhythmia, pruritus, pseudotumor cerebri, pulmonary alveolar hemorrhage, pulmonary edema, pulmonary infiltrates, pulmonary mass, QT interval increased, rash, renal impairment, renal insufficiency, respiratory failure, rhabdomyolysis, SIADH, sinus arrest, skin cancer, spontaneous ecchymosis, Stevens-Johnson syndrome, thrombocytopenia, thyroid nodules, thyroid cancer, thyrotoxicosis, torsade de pointes (rare), toxic epidermal necrolysis, urticaria, vasculitis, ventricular fibrillation, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amiodarone, iodine, or any component; severe sinus node dysfunction; marked sinus bradycardia, second or third degree A-V block; cardiogenic shock; bradycardia-induced syncope (except if pacemaker is placed)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amiodarone HCl contains 37% iodine by weight; avoid use during pregnancy and while breast-feeding (fetal/neonatal goiters, hypothyroidism, and possible cerebral damage may occur); amiodarone may cause hypothyroidism or hyperthyroidism; hyperthyroidism may result in potentially fatal thyrotoxicosis or breakthrough or aggravation of potentially fatal arrhythmias; consider the possibility of hyperthyroidism if any new signs of arrhythmia appear; use with caution and monitor thyroid function closely in patients with thyroid disease (",
"     <b>",
"      Note:",
"     </b>",
"     Oral amiodarone has caused dose-related thyroid tumors in rats; cases of thyroid nodules/thyroid cancer have been reported in patients treated with amiodarone; hyperthyroidism was also present in some of these patients).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amiodarone has several potentially fatal toxicities",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; pulmonary and hepatic toxicities may be fatal. Not considered first-line antiarrhythmic due to high incidence of toxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; 75% of patients experience adverse effects with large doses; discontinuation is required in 5% to 20% of patients. Use of lower amiodarone doses (loading and maintenance) may be associated with a lower incidence of pulmonary toxicity. Early onset pulmonary toxicity (ie, occurring over days to weeks) has been reported with oral amiodarone (with or without initial I.V. use) and may progress to respiratory failure or death. Reserve for use in life-threatening arrhythmias refractory to other therapy. Amiodarone may worsen or precipitate arrhythmias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , including torsade de pointes; when possible, hypokalemia and hypomagnesemia should be corrected prior to I.V. amiodarone use due to increased risk for torsade de pointes. Amiodarone may prolong the QT interval and should not be used in patients with congenital long QT syndrome (Fishberger, 2009). Amiodarone is a potent inhibitor of cytochrome P450 enzymes and p-glycoprotein; serious drug interactions may occur; prolongation of the QT interval, with or without torsade de pointes, has been reported in patients receiving amiodarone concomitantly with macrolide antibiotics, azoles, or fluoroquinolones. Hypotension with I.V. use occurs in about 16% of patients, may be associated with infusion rate, and may be fatal; in adults, I.V. daily doses &gt;2100 mg are associated with greater risk of hypotension; hypotension may respond to slowing the infusion, volume expansion, or administration of calcium, vasopressor drugs, or positive inotropic agents. Bradycardia and AV block may occur; temporary pacemaker should be available when I.V. product is used in patients with known predisposition to bradycardia or AV block. Patients should be hospitalized for initiation of therapy and loading dose administration",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic administration of antiarrhythmic drugs may affect defibrillation or pacing thresholds in patients with implantable cardiac devices (eg, defibrillators, pacemakers); assess thresholds when initiating amiodarone and during therapy. In pediatric patients (n=61, age: 30 days to 15 years), dose-related cardiovascular adverse reactions were common (hypotension 36%, bradycardia 20%, and AV block 15%) and in some cases, severe or life-threatening. Optic neuropathy and/or optic neuritis resulting in visual impairment may occur at any time and can progress to permanent blindness; prompt ophthalmic exam is recommended if visual impairment occurs; re-evaluate amiodarone therapy if optic neuropathy or neuritis occurs. Corneal refractive laser surgery is generally contraindicated in patients receiving amiodarone (per manufacturers of the laser surgery devices).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injectable product contains polysorbate (Tween&reg; 80) and benzyl alcohol; polysorbate 80 or benzyl alcohol may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use amiodarone products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract. In order to decrease the potential exposure of infants to plasticizers, consider the use of bolus dosing in 1 mg/kg aliquots as described by Perry, 1996.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (major), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (moderate), CYP2B6 (weak), CYP2C9 (moderate), CYP2D6 (moderate), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Alfa: Amiodarone may diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Beta: Amiodarone may diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class Ia): Amiodarone may enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).  Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): May enhance the QTc-prolonging effect of Amiodarone. Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Amiodarone may enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Amiodarone may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Amiodarone. Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for increased amiodarone concentrations/effects with cimetidine initiation/dose increase or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Amiodarone may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amiodarone may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Amiodarone may increase the serum concentration of Dabigatran Etexilate.  Management: Canadian (but not U.S.) dabigatran prescribing information recommends limiting dabigatran dose for VTE prevention following hip/knee replacement to 150 mg/day.  No dose adjustment is recommended for dabigatran in atrial fibrillation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Amiodarone may increase the serum concentration of Flecainide.  Management: Decrease flecainide dose by 50% in the presence of amiodarone.  Monitor for adverse effects of flecainide and consider monitoring for elevated serum concentrations during concomitant therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Amiodarone may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease serum concentrations of the active metabolite(s) of Amiodarone. Grapefruit Juice may increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Amiodarone may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Pravastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Amiodarone may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loratadine: Amiodarone may increase the serum concentration of Loratadine.  Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Amiodarone may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the absorption of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amiodarone may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Amiodarone may enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Amiodarone may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of Amiodarone. Telaprevir may increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases rate and extent of oral absorption (high fat meal increased AUC by a mean of 2.3 times). Grapefruit juice increases oral amiodarone AUC by 50% and peak serum concentrations by 84%; avoid grapefruit juice during amiodarone therapy.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm when administered to a pregnant woman, leading to congenital goiter and hypo- or hyperthyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate and rhythm, blood pressure, ECG, chest x-ray, pulmonary function tests, thyroid function tests; serum glucose, electrolytes (especially potassium and magnesium), triglycerides, liver enzymes; ophthalmologic exams including fundoscopy and slit-lamp examinations, physical signs and symptoms of thyroid dysfunction (lethargy, edema of hands and feet, weight gain or loss), and pulmonary toxicity (dyspnea, cough; oxygen saturation, blood gases). Monitor pacing or defibrillation thresholds in patients with implantable cardiac devices (eg, pacemakers, defibrillators) at initiation of therapy and periodically during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1050964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Chronic oral dosing: 1-2.5 mg/L (SI: 2-4 micromoles/L) (parent); desethyl metabolite (active) is present in equal concentration to parent drug; serum concentrations may not be of great value for predicting toxicity and efficacy; toxicity may occur even at therapeutic concentrations",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A class III antiarrhythmic agent which inhibits adrenergic stimulation (possesses alpha- and beta-adrenergic-blocking properties); affects sodium, potassium, and calcium channels; prolongs the action potential and refractory period in myocardial tissue; decreases A-V conduction and sinus node function; possesses vasodilatory and negative inotropic effects",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 2-3 days to 1-3 weeks after starting therapy; I.V.: (electrophysiologic effects) within hours; antiarrhythmic effects: 2-3 days to 1-3 weeks; mean onset of effect may be shorter in children vs adults and in patients receiving I.V. loading doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral: 1 week to 5 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of effects after discontinuation of oral therapy: Variable, 2 weeks to months: Children: less than a few weeks; adults: several months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Slow and incomplete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Amiodarone and its active metabolite cross the placenta; both distribute to breast milk in concentrations higher than maternal plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Rapid redistribution with a decrease to 10% of peak values within 30-45 minutes after completion of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : I.V. single dose in adults: Mean range: 40-84 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Oral dose in adults: 66 L/kg: range: 18-148 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver and possibly the GI tract via cytochrome P450 enzymes; the major metabolite N-desethylamiodarone is active",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: &sim;50% (range: 35% to 65%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amiodarone:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single dose in adults: Mean: 58 days (range: 15-142 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral chronic therapy in adults: Mean range: 40-55 days (range: 26-107 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. single dose in adults: Mean range: 20-47 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Half-life is shortened in children vs adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desethylamiodarone (active metabolite):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single dose in adults: Mean: 36 days (range 14-75 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral chronic therapy in adults: Mean: 61 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Via biliary excretion; possible enterohepatic recirculation; &lt;1% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Nondialyzable (parent and metabolite)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27189?source=see_link\">",
"      see \"Amiodarone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of amiodarone. Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. Avoid grapefruit juice and the herbal medicine, St John's wort. Notify physician or get medical help immediately if shortness of breath, wheezing, chest pain, spitting up of blood, yellow eyes, brown or dark-colored urine, heart pounding, lightheadedness, fainting, weakness, heat or cold intolerance, weight gain or loss, sweating, thinning of hair, changes in menses, swelling of neck (goiter), nervousness, irritability, restlessness, decreased concentration, depression, or tremor occurs. Notify physician if persistent dry cough or decreased vision occurs. May discolor skin to a slate blue color. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conversion of mcg/kg/minute to mg/kg/day units of measure for continuous I.V. administration (",
"     <b>",
"      Note:",
"     </b>",
"     Do",
"     <b>",
"      not",
"     </b>",
"     use for I.V. to oral conversion):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 mcg/kg/minute = 7.2 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10 mcg/kg/minute = 14.4 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     15 mcg/kg/minute = 21.6 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intoxication with amiodarone necessitates ECG monitoring; bradycardia may be atropine resistant, I.V. isoproterenol or cardiac pacemaker may be required; hypotension, cardiogenic shock, heart block, QT prolongation and hepatotoxicity may also be seen; patients should be monitored for several days following overdose due to long half-life",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     I.V. product is used for acute treatment; the duration of I.V. treatment is usually 48-96 hours; however, in adults, infusions may be used cautiously for 2-3 weeks; there is limited experience with administering infusions for &gt;3 weeks",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Thyroid function tests: Amiodarone partially inhibits the peripheral conversion of thyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ) to triiodothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ); serum T",
"     <sub>",
"      4",
"     </sub>",
"     and reverse triiodothyronine (RT",
"     <sub>",
"      3",
"     </sub>",
"     ) concentrations may be increased and serum T",
"     <sub>",
"      3",
"     </sub>",
"     may be decreased; most patients remain clinically euthyroid, however, clinical hypothyroidism or hyperthyroidism may occur.",
"     <b>",
"      Note:",
"     </b>",
"     Amiodarone HCl contains 37% iodine by weight and is a potential source of large amounts of iodine; ~3 mg of inorganic iodine per 100 mg of amiodarone is released into the systemic circulation (RDA for iodine in Adults is 150 mcg).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F133605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg; adjusted to a pH between 6-7 using a sodium bicarbonate solution (5 g/100 mL of distilled water). Crush five 200 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 42 days at room temperature or 91 days refrigerated (preferred) (Nahata, 2004).",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Celiker A, Ceviz N, and Ozme S, &ldquo;Effectiveness and Safety of Intravenous Amiodarone in Drug-Resistant Tachyarrhythmias of Children,&rdquo;",
"      <i>",
"       Acta Paediatr Jpn",
"      </i>",
"      , 1998, 40(6):567-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/9893292/pubmed\" id=\"9893292\" target=\"_blank\">",
"        9893292",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coumel P and Fidelle J, &ldquo;Amiodarone in the Treatment of Cardiac Arrhythmias in Children: One Hundred Thirty-Five Cases,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1980, 100(6 Pt 2):1063-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/7446409/pubmed\" id=\"7446409\" target=\"_blank\">",
"        7446409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE, Sanoski CA, Wiggins BS, et al, &ldquo;Pharmacotherapy Considerations in Advanced Cardiac Life Support,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(12):1703-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/17125434/pubmed\" id=\"17125434\" target=\"_blank\">",
"        17125434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drago F, Mazza A, Guccione P, et al, &ldquo;Amiodarone Used Alone or in Combination With Propranolol: A Very Effective Therapy for Tachyarrhythmias in Infants and Children,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1998, 19(6):445-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/9770567/pubmed\" id=\"9770567\" target=\"_blank\">",
"        9770567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Etheridge SP, Craig JE, and Compton SJ, &ldquo;Amiodarone is Safe and Highly Effective Therapy for Supraventricular Tachycardia in Infants,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2001, 141(1):105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/11136494/pubmed\" id=\"11136494\" target=\"_blank\">",
"        11136494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al, \"ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/16904574/pubmed\" id=\"16904574\" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, and Gillmore D, \"Handbook of Emergency Cardiovascular Care for Healthcare Providers,\" South Deerfield, MA: American Heart Association; 2006.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Figa FH, Gow RM, Hamilton RM, et al, &ldquo;Clinical Efficacy and Safety of Intravenous Amiodarone in Infants and Children,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1994, 74(6):573-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/8074040/pubmed\" id=\"8074040\" target=\"_blank\">",
"        8074040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fishberger SB, Hannan RL, Welch EM, et al, \"Amiodarone for Pediatric Resuscitation: A Word of Caution,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2009, 30(7):1006-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/19495851/pubmed\" id=\"19495851\" target=\"_blank\">",
"        19495851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garson A Jr, Gillette PC, McVey P, et al, &ldquo;Amiodarone Treatment of Critical Arrhythmias in Children and Young Adults,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1984, 4(4):749-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/6384328/pubmed\" id=\"6384328\" target=\"_blank\">",
"        6384328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guarnieri T, Nolan S, Gottlieb SO, et al, \"Intravenous Amiodarone for the Prevention of Atrial Fibrillation After Open Heart Surgery: The Amiodarone Reduction in Coronary Heart (ARCH) Trial,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(2):343-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/10440143/pubmed\" id=\"10440143\" target=\"_blank\">",
"        10440143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haas NA and Camphausen CK, \"Impact of Early and Standardized Treatment With Amiodarone on Therapeutic Success and Outcome in Pediatric Patients With Postoperative Tachyarrhythmia,\"",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 2008, 136(5):1215-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/19026806/pubmed\" id=\"19026806\" target=\"_blank\">",
"        19026806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovacikova L, Hakacova N, Dobos D, et al, \"Amiodarone as a First-Line Therapy for Postoperative Junctional Ectopic Tachycardia,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2009, 88(2):616-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/19632422/pubmed\" id=\"19632422\" target=\"_blank\">",
"        19632422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lane RD, Nguyen KT, Niemann JT, et al, \"Amiodarone for the Emergency Care of Children,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2010, 26(5):382-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/20453797/pubmed\" id=\"20453797\" target=\"_blank\">",
"        20453797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/20956224/pubmed\" id=\"20956224\" target=\"_blank\">",
"        20956224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paul T and Guccione P, &ldquo;New Antiarrhythmic Drugs in Pediatric Use: Amiodarone,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1994, 15(3):132-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/8047495/pubmed\" id=\"8047495\" target=\"_blank\">",
"        8047495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry JC, Fenrich AL, Hulse JE, et al, &ldquo;Pediatric Use of Intravenous Amiodarone: Efficacy and Safety in Critically Ill Patients From a Multicenter Protocol,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1996, 27(5):1246-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/8609351/pubmed\" id=\"8609351\" target=\"_blank\">",
"        8609351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raja P, Hawker RE, Chaikitpinyo A, et al, &ldquo;Amiodarone Management of Junctional Ectopic Tachycardia After Cardiac Surgery in Children,&rdquo;",
"      <i>",
"       Br Heart J",
"      </i>",
"      , 1994, 72(3):261-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/ 7946778 /pubmed\" id=\" 7946778 \" target=\"_blank\">",
"        7946778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roy D, Talajic M, Dorian P, et al, \"Amiodarone to Prevent Recurrence of Atrial Fibrillation. Canadian Trial of Atrial Fibrillation Investigators,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(13):913-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/10738049/pubmed\" id=\"10738049\" target=\"_blank\">",
"        10738049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shahar E, Barzilay Z, Frand M, et al, &ldquo;Amiodarone in Control of Sustained Tachyarrhythmias in Children With Wolff-Parkinson-White Syndrome,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1983, 72(6):813-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/6646922/pubmed\" id=\"6646922\" target=\"_blank\">",
"        6646922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shuler CO, Case CL, and Gillette PC, &ldquo;Efficacy and Safety of Amiodarone in Infants,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1993, 125(5 Pt 1):1430-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/8480599/pubmed\" id=\"8480599\" target=\"_blank\">",
"        8480599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skrifvars MB, Kuisma M, Boyd J, et al, \"The Use of Undiluted Amiodarone in the Management of Out-of-Hospital Cardiac Arrest,\"",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 2004, 48(5):582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/15101852/pubmed\" id=\"15101852\" target=\"_blank\">",
"        15101852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soult JA, Munoz M, Lopez JD, et al, &ldquo;Efficacy and Safety of Intravenous Amiodarone for Short-Term Treatment of Paroxysmal Supraventricular Tachycardia in Children,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1995, 16(1):16-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/7753695 /pubmed\" id=\"7753695 \" target=\"_blank\">",
"        7753695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vorperian VR, Havighurst TC, Miller S, et al, \"Adverse Effects of Low Dose Amiodarone: A Meta-analysis,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 30(3):791-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/9283542/pubmed\" id=\"9283542\" target=\"_blank\">",
"        9283542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimetbaum P, \"Amiodarone for Atrial Fibrillation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(9):935-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/41/9882/abstract-text/17329700/pubmed\" id=\"17329700\" target=\"_blank\">",
"        17329700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12587 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-A67B6C3D87-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9882=[""].join("\n");
var outline_f9_41_9882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708616\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133629\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133630\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050961\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431485\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050953\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133598\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133581\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874279\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050966\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471287\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133689\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050956\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050965\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133691\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133688\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050971\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050952\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050951\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133676\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133590\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050974\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133593\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050960\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050964\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050950\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050969\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050970\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050958\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050972\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133605\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=related_link\">",
"      Amiodarone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27189?source=related_link\">",
"      Amiodarone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_41_9883="Ramsay sedation scale";
var content_f9_41_9883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The Ramsay sedation scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Clinical score",
"      </td>",
"      <td class=\"subtitle1\">",
"       Patient characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Awake; Agitated or restless or both",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Awake; Cooperative, oriented, and tranquil",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Awake but responds to commands only",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       Asleep; brisk response to light glabellar tap or loud auditory stimulus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       Asleep; sluggish response to light glabellar tap or loud auditory stimulus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Asleep; no response to glabellar tap or loud auditory stimulus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Ramsay, MA, Savage, TM, Simpson, BR, Goodwin, R, Br Med J 1974; 2:656.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9883=[""].join("\n");
var outline_f9_41_9883=null;
var title_f9_41_9884="Techniques of termination phase of Interpersonal Psychotherapy";
var content_f9_41_9884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F67730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F67730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Techniques of the termination phase of Interpersonal Psychotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strategy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess treatment progress and reinforce treatment gains",
"       </td>",
"       <td>",
"        Review serial scores on standardized, self-report depression rating instrument and gains made in interpersonal problem area over the course of therapy.",
"       </td>",
"       <td>",
"        Highlight treatment gains, which are usually considerable, and acknowledge residual symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss remaining treatment needs and options",
"       </td>",
"       <td>",
"        Evaluate need for ongoing psychotherapy, augmentation with other treatment modalities such as pharmacotherapy, or change of treatment strategies.",
"       </td>",
"       <td>",
"        Consider ongoing, monthly, maintenance IPT to consolidate and preserve treatment gains.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticipate future vulnerability to recurrence of depression",
"       </td>",
"       <td>",
"        Revisit the link between one's current life events and depression, to help the patient identify periods of risk and strategies to prevent recurrence of symptoms.",
"       </td>",
"       <td>",
"        Establish a plan for seeking treatment in the future if depression recurs, ie, recontact the clinician or contact the primary care physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss feelings associated with termination",
"       </td>",
"       <td>",
"        Normalize feelings of sadness and loss arising at the end of psychotherapy, and differentiate these feelings from symptoms of depression.",
"       </td>",
"       <td>",
"        Probe for feelings associated with termination even if patient does not spontaneously volunteer them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blame the therapy&mdash;and not the patient&mdash;for incomplete remission",
"       </td>",
"       <td>",
"        If therapy has failed to bring about complete resolution of the depressive episode, blame the therapy and not the patient.",
"       </td>",
"       <td>",
"        The clinician should remain optimistic, and encourage the patient to continue treatment of the depressive episode. The availability of numerous pharmacotherapy and psychotherapy options should be emphasized.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9884=[""].join("\n");
var outline_f9_41_9884=null;
var title_f9_41_9885="Methods for assessment of macrosomia";
var content_f9_41_9885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods for assessment of macrosomia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Method",
"      </td>",
"      <td class=\"subtitle1\">",
"       Reference",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sensitivity, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specificity, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       PPV, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       NPV, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maternal estimate, parous women &gt;4000 g",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       56",
"      </td>",
"      <td>",
"       94",
"      </td>",
"      <td>",
"       77",
"      </td>",
"      <td>",
"       86",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clinician's estimates &gt;4000 g",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       10 to 43",
"      </td>",
"      <td>",
"       99.0 to 99.8",
"      </td>",
"      <td>",
"       28 to 53",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sonographic estimates",
"      </td>",
"      <td>",
"       1, 3-17",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"6\" rowspan=\"1\">",
"       1. AC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4000 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       77",
"      </td>",
"      <td class=\"sublist_other\">",
"       75",
"      </td>",
"      <td class=\"sublist_other\">",
"       91",
"      </td>",
"      <td class=\"sublist_other\">",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4500 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       89",
"      </td>",
"      <td class=\"sublist_other\">",
"       94",
"      </td>",
"      <td class=\"sublist_other\">",
"       93",
"      </td>",
"      <td class=\"sublist_other\">",
"       89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Serial ACs",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       84",
"      </td>",
"      <td>",
"       94",
"      </td>",
"      <td>",
"       93",
"      </td>",
"      <td>",
"       89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. FL and AC",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       63",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       68",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. AC and BPD",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       65",
"      </td>",
"      <td>",
"       90",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"6\" rowspan=\"1\">",
"       5. BPD and AC and FL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4000 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       71",
"      </td>",
"      <td class=\"sublist_other\">",
"       92",
"      </td>",
"      <td class=\"sublist_other\">",
"       55",
"      </td>",
"      <td class=\"sublist_other\">",
"       96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4500 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       22 to 44",
"      </td>",
"      <td class=\"sublist_other\">",
"       99",
"      </td>",
"      <td class=\"sublist_other\">",
"       30 to 44",
"      </td>",
"      <td class=\"sublist_other\">",
"       97 to 99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       6. BPD and AC and FL",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       86",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       95",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       -",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Adjusted by maternal characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Abdominal wall thickness greater than 11 mm",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       96",
"      </td>",
"      <td>",
"       less than 50",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; NPV: negativepredictive value; AC: abdominal circumference; FL: femur length; BPD:biparietal diameter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9885=[""].join("\n");
var outline_f9_41_9885=null;
var title_f9_41_9886="ABL1 and BCR genes in CML";
var content_f9_41_9886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    ABL1 and BCR genes in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 407px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A schematic representation of the ABL1 gene on chromosome 9 (A) and the BCR gene on chromosome 22 (B). All exons (red/blue boxes) have been scaled to the same size for clarity. Exon numbers are indicated above the coding sequence and the breakpoint cluster nomenclature is placed below the M-bcr (b1-b5). Introns are represented by the intervening lines. The various breakpoint regions are identified by double-headed arrows. The schematic fusion transcripts for the typical M-, m-, and &micro;-bcr are illustrated (C), while the translocation product is demonstrated on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9886=[""].join("\n");
var outline_f9_41_9886=null;
var title_f9_41_9887="SSDI application appeal process";
var content_f9_41_9887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    SSDI application and appeals process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 665px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Carey TS, Hadler NM. Ann Intern Med 1986; 104:706.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_41_9887=[""].join("\n");
var outline_f9_41_9887=null;
